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Effects of Extended Exercise and Carbohydrate Feedings on Substrate Oxidation and 
Muscle Giycogenolysis
Chairperson; Dr. Brent C. Rub
PURPOSE: The purpose of this study was to examine the effects of exogenous 
carbohydrate intake during eight hours of prolonged exercise on muscle giycogenolysis 
and whole-body substrate oxidation. METHODS: Eight recreationally-trained males 
participated in two 8-hour exercise trials. During each hour, subjects repeated 25 minutes 
cycle ergometer exercise, 5 minutes rest, 25 minutes treadmill exercise, and 5 minutes 
rest. Each 25 minute exercise segment consisted of two steady state and three interval 
work bouts. Muscle biopsies were obtained pre- and post-exercise. Blood samples were 
collected pre-exercise, after hour 4, and post-exercise. Metabolic gases were collected 
during hours 1 ,4 ,5 , and 8. Every 15 minutes, subjects ingested 150 mL of either a 10% 
carbohydrate solution (CHO) or a sweetened placebo (PLA). Subjects were provided 
with a standardized breakfast and lunch. Data were analyzed using repeated-measures 
ANOVA and statistical significance was set at p<0.05. RESULTS: There was a 
significant difference in the rate of muscle giycogenolysis between trials (9.4 ±2.1 and 
13.7 ± 4.6 mmol kg wet wt. ' hr ' for CHO and PLA, respectively). Rates of whole-body 
carbohydrate oxidation demonstrated a general maintenance throughout exercise for the 
CHO trial but showed a decline throughout the PLA trial. Blood glucose and insulin 
were higher for CHO after hour 4 and post exercise compared to PLA. CONCLUSION: 
The results fi'om this study suggest that regular exogenous carbohydrate feedings during 
prolonged, intermittent exercise attenuate muscle giycogenolysis while maintaining 
plasma glucose and insulin concentrations and rates of whole-body carbohydrate 
oxidation.
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Chapter One: 
Introduction 
Introduction:
The fatigue-delaying and performance-enhancing effects o f carbohydrate (CHO) 
supplementation during physical work and exercise have consistently been demonstrated 
(26, 78, 98). While the improved work-capacity and performance benefits o f  ingesting 
CHO during extended exercise appear conclusive, the mechanism underlying this 
phenomenon remains unclear. Some researchers argue the delay in the onset o f fatigue is 
due to preservation o f muscle glycogen (8, 31, 97, 111), others contend that it is due to 
maintenance o f euglycemia (4, 22, 26, 40), while even others insist that it is not either of 
these metabolic factors but rather factors associated with central fatigue (17, 73, 91).
Most likely, all three o f  these factors contribute to the complex event o f  overall fatigue. 
The prevalence of these mechanisms may depend on other factors such as the type and 
intensity o f exercise, amount, type, and timing o f CHO ingestion, pre-exercise nutritional 
and training status, as well as psychological factors such as motivation and boredom.
Most research has examined moderate to high intensity exercise performed for 
four or less hours and has established the fatigue-delaying affects o f CHO ingestion 
during activities o f such intensities and durations (40, 87, 97, 98, 100). In the fasted 
state, muscle glycogen may provide as much as 80% of the total CHO oxidized during 
moderate-high intensity exercise (13). Furthermore, a study by Vollestad and Blom (104) 
demonstrates that type I muscle fibers become glycogen depleted after only 60 minutes of 
low intensity exercise. Muscle glycogen is clearly essential as an energy-producing
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
substrate. Therefore, carbohydrate supplementation becomes even more critical during 
prolonged activities (i.e. lasting longer than four hours). It cannot be assumed, however, 
that whole-body and muscle metabolism are similar during exercise lasting 4 hours 
compared to exercise lasting 6, 8, or even 10 hours. The metabolic response during 
extended exercise (exercise lasting longer than 4 hours) requires further investigation.
In conjunction with the issue o f delaying fatigue via CHO supplementation are the 
influences of CHO bioavailability and oxidation. Obviously, the maximal performance 
benefit is going to be elicited by the optimal CHO feeding strategy. Much work has been 
done in this area to determine the best type, concentration, and amount of CHO to ingest. 
It seems that a combination o f sugar types, rather than a single sugar, promotes the 
greatest absorption and subsequent oxidation o f exogenous carbohydrate sources (61), 
while increasing concentration does not necessarily correlate with improvement in 
oxidation (61). These issues also need to be considered during exercise lasting longer 
than 4 hours.
Thus, while previous research has contributed significantly to our current 
knowledge of CHO metabolism during exercise, more research is necessary to explain 
substrate utilization and muscle giycogenolysis during varied-intensity activities lasting 
longer than four hours.
Statement of the Problem:
Nearly all the research regarding carbohydrate supplementation and substrate 
oxidation during exercise has been done while examining exercise bouts o f four hours or 
less. Substrate metabolism and muscle glycogen utilization are not as well understood
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
during exercise lasting longer than four hours. Although there are few physically 
demanding jobs in today’s technologically driven world, those that do exist consist of 
work shifts much longer than four hours. Issues o f fatigue and cognitive ability become 
especially important late in the work shift. An understanding o f metabolism during 
longer duration activity is necessary and is critical for determining what actions can be 
taken to attenuate the development o f fatigue and keep people cognizant and safe 
throughout the entire work shift.
Purpose:
The purpose o f this research is to determine the effects o f carbohydrate 
supplementation on whole body substrate oxidation, muscle giycogenolysis, and changes 
in blood glucose, lactate, and insulin concentrations during eight hours o f moderate 
exercise interspersed with higher intensity intervals.
Research Questions:
(1). How does regular carbohydrate supplementation during prolonged, varied 
intensity exercise affect muscle giycogenolysis?
(2). How does regular carbohydrate supplementation during prolonged, varied 
intensity exercise affect carbohydrate and fat oxidation (as measured indirectly through 
metabolic gas collection)?
(3). How does regular carbohydrate supplementation during prolonged, varied 
intensity exercise affect blood glucose, lactate, and insulin concentrations?
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(4). How does regular carbohydrate supplementation during prolonged, varied 
intensity exercise affect heart rate, rate o f perceived exertion (RPE), and cycle cadence?
Research Hypotheses:
(1). Muscle glycogen oxidation will be lower during the CHO trial compared to the 
placebo trial.
(2). Whole body carbohydrate oxidation will be higher during the CHO trial compared 
to the placebo trial.
(3). Whole body fat oxidation will be lower during the CHO trial compared to the 
placebo trial.
(4). Blood glucose concentration will be higher after hours 4 and 8 of exercise during 
the CHO trial compared to the placebo trial. There will be no difference between the 
trials in pre-exercise blood glucose concentrations.
(5). Insulin concentration will be higher after hours 4 and 8 o f  exercise during the 
CHO trial compared to the placebo trial. There will be no difference between the trials in 
pre-exercise insulin concentrations.
(6). Lactate concentration will be significantly lower after hours 4 and 8 o f  exercise 
during the CHO trial compared to the placebo trial. There will be no difference between 
the trials in pre-exercise lactate concentrations.
(7). Average heart rate will be lower throughout the CHO trial compared to the 
placebo trial.
(8). Average RPE will be lower throughout the CHO trial compared to the placebo 
trial.
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(9). Average cycle cadence will be higher during the CHO trial compared to the 
placebo trial.
Limitations:
There are many factors which influence whole-body metabolism. We are not able to 
control and/or account for all o f  them.
Gas exchange is an indirect means o f determining ventilatory threshold (VT) and 
substrate oxidation and can be interpreted only as an estimate. The use o f indirect 
methods, though non-invasive and easily performed, increases measurement error.
Muscle biopsy locations are slightly different pre- and post-exercise and may not 
accurately reflect changes in muscle glycogen concentration.
The use o f any instrumentation invites inherent error. In an attempt to limit the 
occurrence o f errors, all researchers will be adequately trained and equipment will be 
carefully calibrated.
Delimitations:
The results o f this study can only be extrapolated to other males o f similar age and fitness 
level.
The exercise was performed on a cycle ergometer and treadmill in a laboratory-controlled 
environment and may not be transferable to real-life or field-type situations.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Exercise intensity was controlled throughout the trials. In a real-life setting individuals 
will adapt an exercise intensity to match fatigue and motivation levels.
Definition of Terms:
Carbohydrate (CHO). The treatment subjects received during one o f their two trials. 
Carbohydrate was provided in liquid form at predetermined time points throughout the 
exercise session.
Placebo (TLA). The treatment subjects received during one o f their two trials. An 
artificially sweetened drink was provided at predetermined time points throughout the 
exercise session.
Ventilatory Threshold (Tvent). The intensity relative to which the exercise trials were set. 
VT is an indicator o f  one’s fitness level and is based on nonlinear increases in metabolic 
gases. VT was estimated using a combination o f the v-slope, excess CO2 , and the 
ventilatory equivalents methods. VT was considered to be the first sustained rise in 
VeA^Oi without a concomitant rise in Ve/VCOz (ventilatory equivalents method), 
concurrent with the fibrst rise in excess CO2 (excess CO2 method), and the first break 
above a slope o f 1.0 when VO2 is plotted versus VCO2 (v-slope method).
VOymax. The maximal amount o f oxygen an individual consumes during a graded 
exercise test to volitional exhaustion.
Glycolysis. A cellular energy-producing pathway via the oxidation o f glucose.
6
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Glucose. A sugar and the primary source o f energy for living organisms. It is the only 
form o f carbohydrate which can undergo glycolysis and ultimate result in energy 
production.
Lactate. A biproduct o f glycolysis which may enter muscle cells and in turn be oxidized 
to produce energy.
Insulin. A hormone secreted by the pancreas and responsible for regulating glucose 
levels in the blood. It aids in the uptake o f  glucose by muscle and other tissues. 
Glvcosen. The storage form o f glucose molecules. Multiple glucose molecules are 
linked together and stored in either the liver or muscle tissue and degraded for energy as 
demanded.
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Chapter Two: 
Review of Literature 
Causes of fatigue
Krogh and Lindhardt, in the 1920’s, were likely among the first to recognize the 
importance o f CHO as an energy-producing substrate during exercise. They reported that 
subjects perceived exercise to be easier if  it followed a CHO-rich diet versus a high-fat 
diet (66). Furthermore, Levine and colleagues (70) suggested that low blood glucose 
levels were likely a cause o f fatigue o f participants in the 1923 Boston Marathon and 
commented on the correlation between the “blood sugar level and the physical condition 
o f the runner at the finish”. Research by Christensen and Hansen (19) demonstrated a 
relationship between exercise intensity and the muscle’s choice o f substrate by assessing 
indirect measures o f  whole body gas exchange. While measurements of blood glucose 
concentrations and estimations o f substrate utilization were significant in recognizing the 
importance o f CHO during physical activity, it was studies in the 1960’s, which 
reintroduced the muscle biopsy technique, that indicated the critical role o f muscle 
glycogen as a CHO energy-producing substrate (6, 7).
Subsequent research has produced a debate as to how carbohydrate elicits a 
fatigue-delaying effects. Some researchers contend carbohydrate supplementation during 
exercise delays the onset o f fatigue by slowing muscle glycogen oxidation (8, 31, 97,
111), while others insist it is the maintenance o f euglycemia via carbohydrate 
supplementation that allows a person to continue exercising (4, 22,40, 79). Yet others
8
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contend fatigue is not purely a metabolic phenomenon, but is due to the breakdown o f 
some central process (17, 27,28, 29, 73, 91, 105).
Fatigue associated with muscle glycogen concentrations:
The results o f a study by Yaspelkis and colleagues (111) led to the conclusion that 
CHO supplementation could enhance prolonged, variable-intensity exercise via 
conservation o f muscle glycogen. They evaluated muscle glycogen utilization and 
endurance performance in 7 well-trained cyclists. Subjects performed 3 exercise trials to 
fatigue with intensity varying between 45% VOzmax and 75% VOimax. During each of 
the 3 trials subjects received either a artificially sweetened placebo drink, a 10% CHO 
liquid solution, or a solid CHO supplement providing 50 g CHO/h. Muscle biopsies were 
performed before exercise, after the first set o f intervals (124 minutes of exercise), and 
after the second set o f intervals (190 minutes o f exercise). After the 190-minute biopsy, 
subjects cycled to exhaustion at 80% VOzmax. The time to fatigue for the liquid and 
solid CHO trials did not differ, but both were significantly longer than the placebo trial. 
After 190 minutes muscle glycogen concentrations were significantly greater in the CHO 
trials than the placebo trial. These researchers ultimately concluded that the increased 
time to fatigue during the trials in which CHO was provided was due to a reduced 
dependency on muscle glycogen during the previous 190 minute trial.
Studies which have compared the ergogenic effects o f glucose and fructose have 
also demonstrated the muscle glycogen sparing affect o f glucose (8, 31). Total time to 
exhaustion was significantly longer during continuous exercise at 68% VOimax when 
glucose was ingested versus fructose or water (8). Fructose ingestion maintained
9
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euglycemia but failed to attenuate muscle glycogen degradation or improve performance, 
providing evidence that fatigue is associated with muscle glycogen content, not blood 
glucose concentration.
Tsintzas has also demonstrated that delayed time to fatigue is associated with 
conservation o f muscle glycogen, however, he contends the sparing o f muscle glycogen 
is limited to type I (slow-twitch) fibers only (97, 98). During one study Tsintzas (98) had 
8 recreational male runners complete 2 trials (1-placebo, 1-5.5% CHO solution) at 70% 
VOimax until exhaustion. Muscle biopsies performed before exercise, at the time of 
exhaustion (placebo & CHO), and during the CHO trial, at the time corresponding to 
fatigue during the placebo trial, illustrated a 25% reduction in muscle glycogen utilization 
in type I fibers. Furthermore, in both trials, type I but not type II fibers were glycogen 
depleted at the point o f exhaustion—suggesting selective depletion o f type I fibers is 
slower with CHO supplementation. During the CHO trial, blood glucose contributed 
more to total CHO oxidation, however, no signs or symptoms o f hypoglycemia were 
observed during placebo trial— even at the point o f  fatigue. Time to exhaustion when 
CHO was supplemented was ~ 28 minutes longer than when placebo was ingested. Thus, 
the results o f this study suggest fatigue is associated with depletion o f  glycogen in type I 
muscle fibers. Similar results were produced in another study by Tsintzas (97) in which 
cyclists rode for a predetermined time (60 minutes) at 70% VOzmax—again, muscle 
glycogen (type I fibers only) was conserved when CHO was ingested.
The absolute muscle glycogen concentration may determine the point o f fatigue, 
while the rate o f  its oxidation may play a role in the regulation o f pace during extended 
exercise. In a study in which cyclists rode for 120 minutes at ~ 73% V02max (which
10
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included sprints o f 100% peak power output every 20 minutes, followed by a one-hour 
time trial), time trial performance was improved after carbohydrate loading. End muscle 
glycogen concentrations, however, were not different between the non-loaded and 
carbohydrate loaded trials— in fact, they were remarkably similar ( 1 8 ± 3 v .  2 0 ± 3  
mmol/kg w/w). The authors concluded that diet-induced changes o f  muscle glycogen 
content may have influenced integrated feedback from the periphery and ultimately 
affected power output and pacing strategies (88).
Fatigue associated with blood glucose concentrations:
A  study by Coyle, Coggan, and their colleagues (26) was specifically organized to 
determine if  postponement o f  fatigue was associated with muscle glycogen sparing. 
Seven, well-trained, male cyclists performed two trials at ~ 71% VOimax until 
exhaustion; the first trial a sweetened placebo drink was administered, and the second 
trial a glucose polymer drink was administered. The trials were not randomized because 
the aim o f the study was to compare “fed exercise” muscle glycogen oxidation rates and 
concentrations to muscle glycogen oxidation rates and concentrations after a fatiguing 
bout o f exercise without CHO supplementation. Thus, muscle biopsies were performed 
prior to exercise, after 2 hours o f  exercise, at the time o f fatigue during the placebo trial 
(for both trials), and at the time o f fatigue during the fed trial. The average time to 
fatigue during the placebo trial was about 3 hours; the average time to fatigue during the 
CHO-fed trial was about 4 hours. Muscle glycogen utilization did not differ between the 
two trials. The additional exercise when the subjects were fed CHO was performed with
11
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relatively little reliance on muscle glycogen and was attributed to a maintenance o f blood 
glucose concentrations.
Another study by Coggan and Coyle (21) showed delayed fatigue times and 
restoration o f euglycemia by a single CHO feeding late in exercise. They again assert that 
the increase in CHO oxidation resulting from the restoration/maintenance o f euglycemia 
delayed fatigue.
A study by Arkinstall (4) compared muscle glycogen utilization during different 
modes o f exercise; cycling and running. It was hypothesized that, when fed CHO, 
muscle glycogen oxidation would be attenuated during running but not during cycling. 
Subjects cycled and ran at their approximate lactate threshold (LT) for 60 minutes, twice 
for each mode (4 trials total per subject). During the fed trials subjects ingested a 6.4% 
solution (8 ml/kg) 10 minutes before exercise and 2 ml/kg at 20 and 40 minutes into 
exercise. A sweetened placebo was ingested at these same time points during the placebo 
trials. A tracer ( '̂’C) was infused during each trial in order to measure plasma glucose 
oxidation. In contrast to the researchers’ hypothesis, muscle glycogen utilization was not 
decreased with CHO ingestion during either cycling or running. However, the 
contribution o f plasma glucose to total CHO oxidation was significantly increased during 
both modes o f exercise.
Studies by Hargreaves (40) and Mitchell (79) provide further support for the 
notion that fatigue is delayed due to maintenance o f euglycemia, not attenuation o f 
muscle glycogen oxidation. Hargreaves (40) did not find differences in muscle glycogen 
concentrations before and following 2 separate, 120-minute cycling trials at 70%
VOimax (one with CHO supplementation, one with a sweetened water drink). A similar
12
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study by Mitchell (79) examined the affects o f various concentrations o f CHO solutions 
and found no difference in muscle glycogen utilization. Blood glucose concentrations, 
however, were significantly increased when the subjects ingested 12 and 18% solutions 
o f  CHO.
Other cam es o f  fatigue:
Carbohydrate ingestion may delay fatigue, either by maintaining blood glucose 
concentrations or attenuating muscle glycogen oxidation, but it does not prevent 
fatigue— suggesting factors other than CHO availability eventually cause fatigue. 
Alternative causes o f fatigue have been suggested: depletion o f muscle potassium (94), 
decrease in the force-generating capacity o f the myofibril (106), depletion o f  metabolic 
intermediates (95), or fatigue o f neural/central origin versus metabolic/peripheral (17, 27, 
28,29, 105).
It has been demonstrated that at muscular exhaustion the intracellular potassium 
concentration [K] is decreased by 20-40 mM. Thus, it is suggested that when the K- 
gradient across the membrane o f the sarcoplasmic reticulum decreases to a certain 
(threshold) level, excitability o f the muscle is impaired, thereby decreasing the 
contractility o f the muscle fibers— indicative o f fatigue (94).
Vollestad (105, 106) has performed experiments which suggest fatigue is due to a 
decrease in the force-generating capacity o f muscle fibers which results from excitation- 
contraction coupling failure. Subjects performing single-legged quadriceps contractions 
at 30% maximal voluntary contraction (MYC) for 6 s, with 4 s rest between contractions, 
showed a 40% decline in MYC after only 30 minutes o f exercise. Blood samples.
13
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
however, indicated only minor changes in the energy substrates necessary to produce 
muscle contraction—glycogen, lactate, creatine phosphate (CrP), and adenosine 
triphosphate (ATP). The decline in MVC was attributed to a failure o f excitation- 
contraction coupling.
Others have suggested that fatigue ensues because o f the depletion o f certain 
metabolic intermediates and the corresponding accumulation o f other metabolic 
markers—thus affecting the overall muscle energy balance. The results o f studies by 
Spencer (95) and McConell (78) suggest that carbohydrate supplementation prolongs 
time to fatigue by attenuating inosine monophosphate (IMP) accumulation (which is 
associated with muscle glycogen depletion). Spencer had subjects cycle at -70%  
VOzmax until exhaustion, while ingesting a placebo solution, and on a second occasion at 
the same work load and duration, but receiving a 7.5% CHO solution. Subjects were able 
to cycle for an average o f 21.6 minutes longer when receiving the CHO beverage.
Muscle biopsies taken before and after exercise revealed the sum of hexose 
monophosphates (HMP) (intermediates for the Kreb’s/TCA Cycle) was higher after 
exercise with CHO, whereas the accumulation o f IMP was markedly reduced. Thus, 
there is an inverse relationship between HMP and IMP. Fatigue is associated with 
depletion o f HMP and accumulation o f IMP, and attenuation o f these occurrences and 
improvement o f muscle energy balance, prolongs the onset o f fatigue.
The central fatigue hypothesis, though relatively unexplored, suggests that fatigue 
is associated with an increase in brain serotonin (5-HT) levels. Evidence from studies by 
Davis (27, 28, 29) suggest a relationship between 5-HT levels and exercise performance. 
Exercise-induced changes in the ratio between plasma free tryptophan (F-TRP) and
14
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
branched-chain amino acids (BCAA) significantly alters brain 5-HT which, in turn, has 
predictive effects on exercise performance. Essentially, an increase in the 
f-TRP/BCAA ratio results in an increase in 5-HT, which is associated with central 
fatigue. A study (27) in which cyclists exercised at their lactate threshold (~ 68% 
V02max) until fatigue while ingesting either a placebo, 6% or 12% CHO solution 
illustrated a five- to sevenfold increase in f-TRP/BCAA when subjects ingested the 
placebo solution. The increase in this ratio was significantly attenuated with the CHO 
solution. Exercise time to fatigue averaged 190, 235, and 234 minutes when receiving 
the placebo, 6% CHO solution, and 12% CHO solution, respectively.
An interesting study by Carter et al. (17) lends support to the idea that 
performance improvement via CHO supplementation is related to central mechanisms, 
not metabolic factors. Trained cyclists received a CHO solution or an identically-tasting 
placebo. Subjects were not allowed to swallow either drink; it was swished around in the 
mouth and spat out after a 5 second rinse. Time trial performance, measured in average 
watt output and time to completion, was significantly improved when receiving the CHO 
mouth rinse compared to the placebo mouth rinse. These results suggest that there are 
receptors within the oral cavity which are communicating with the brain and central 
factors are mediating exercise performance. In a similar study by Carter (18), when the 
oral cavity was by-passed and glucose was administered via venous infusion, 60-minute 
time trial performance did not differ from when saline was infused.
Effect of CHO ingestion on muscle giycogenolysis
15
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Muscle glycogen and blood glucose, either endogenously provided by the liver or 
exogenously derived, comprise the total carbohydrate (CHO) source for ATP production 
during exercise. Muscle glycogen becomes especially important with increasing exercise 
intensity. In the fasted state, muscle glycogen may provide as much as 80% o f  the total 
CHO oxidized during moderate-high intensity exercise. Thus, despite an increase in 
glucose oxidation as exercise intensity increases, glycogen is more important as a 
substrate. With increasing intensity glycogen breakdown is greatly accelerated and 
glycogen, not glucose, is the major precursor for glycolysis (13). A study by Vollestad 
and Blom (104) demonstrates that muscle fibers become glycogen depleted during low 
intensity exercise as well. After only 60 minutes o f exercise at 43% VOzmax nearly 50% 
of type I fibers are glycogen depleted. Another study conducted by Febbraio and Dancey 
(32) indicated that glycogen availability is a limiting factor during prolonged exercise 
(155-217 minutes) below the lactate threshold. These observations have led many 
scientists to agree that intramuscular glycogen stores are the most important limiting 
factor o f exhaustive exercise and as exercise continues, regardless o f the intensity level, 
muscle glycogen stores become depleted and an exogenous source o f CHO is necessary 
to maintain CHO oxidation. Much research has focused on the possibility o f conserving 
muscle glycogen or attenuating its oxidation, via exogenous CHO supplementation, in 
order to delay the onset o f fatigue. The research has produced conflicting results.
Jeukendrup et al. (59) reported muscle glycogen oxidation rates, indirectly 
estimated from stable isotope tracer infusion (total CHO oxidation minus plasma glucose 
oxidation), were not attenuated even with glucose ingestion rates as high as 180 
grams/hour. Similarly, Flynn et al. (35) measured muscle glycogen concentration
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directly with biopsy technique and reported oxidation was not influenced by ingestion o f 
various CHO-% solutions throughout 2 hours o f cycling. In contrast, Yaspelkis et al. 
( I l l )  reported increased time to fatigue and decreased muscle glycogen utilization during 
continuous, varying-intensity exercise while drinking a 10% liquid CHO solution or 
eating a solid CHO supplement. These results were repeated in a study where cyclists 
rode at a constant intensity (~ 68% VOzmax) until exhaustion (8) and in a study where 
cyclists rode for 90 minutes at 65-70% VOimax (31).
Inconsistencies and varying results are present even between the results of 
separate studies conducted by the same scientists. Hargreaves and Briggs (40) had five 
competitive male cyclists ride for 120 minutes at ~ 70% VOzmax on two different 
occasions. During the experimental trial subjects ingested 30 g o f CHO at 0, 30, 60, and 
90 minutes. They ingested a sweetened placebo at these same time points during the 
other trial. Muscle samples taken pre- and post-exercise revealed no difference in muscle 
glycogen concentration or oxidation rate. However, another study conducted by 
Hargreaves, Costill, and Coggan (39) in which subjects were studied during 4 hours o f 
cycling to determine the effect o f solid CHO feedings on muscle giycogenolysis and 
exercise performance revealed significantly lower muscle glycogen utilization during the 
CHO trial compared to the placebo trial. Contrary to the results o f this study, other 
research conducted by Costill and Coggan has not demonstrated a decrease in muscle 
giycogenolysis and has attributed any improvement in performance to maintenance o f 
euglycemia (26, 35, 79).
Tsintzas has consistently demonstrated a decrease in muscle giycogenolysis when 
subjects are fed CHO during exercise (97, 98). His method o f glycogen analysis is
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sensitive enough to detect changes within fiber-type populations (i.e. slow- or fast-twitch 
fibers). Consequently, the results o f  these studies have revealed that conservation o f 
muscle glycogen can occur during low to moderate intensity exercise, but it is generally 
limited to type I (slow-twitch) fibers. Thus, while mixed glycogen utilization was 
reduced 25% in a study where males ran at ~  70% VO^max until exhaustion, closer 
analysis revealed this was attributed to a reduction o f glycogenolysis within type I fibers 
and there was no significant difference between trials o f  glycogenolysis within type II 
fibers, which showed little glycogenolysis (98).
Research by Kuipers and colleagues suggests that CHO ingestion during exercise 
that is either intermittent or o f low enough intensity may actually stimulate glycogen 
synthesis in the non-active muscle fibers (64, 68, 69). In one o f these studies, seven male 
cyclists performed intermittent exercise until exhaustion. Upon exhaustion, a muscle 
biopsy was performed, after which subjects either continued to exercise at 40% VOzmax 
for 3 hours or rested for 3 hours. During both occasions, subjects ingested 2 liters o f a 
25% maltodextrin solution. After the 3 hours o f exercise or rest another muscle biopsy 
was taken. Analysis revealed that muscle glycogen concentration increased during both 
trials from the concentration post exhaustive exercise. However, the glycogen 
resynthesis was restricted to type II fibers during exercise whereas glycogen resynthesis 
occurred in both type I and type II fibers during rest (69). Nonetheless, this demonstrates 
that CHO supplementation may not only provide substrate for ATP production during 
exercise, but may also contribute to replenishment o f glycogen in non-active muscle 
fibers.
18
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These variable results, both between and within different laboratories, could very 
well be attributed to differences in testing protocols (type and amount o f CHO provided, 
fed state before exercise, duration and intensity o f  exercise) and sensitivity o f analysis 
techniques— as pointed out by Tsintzas. By far, the most frequently mode o f  exercise 
employed in these studies is cycling. Running and other types o f  activity elicit a different 
type o f physiological and metabolic response (30, 47, 65), and thus, muscle glycogen 
utilization differs. Furthermore, metabolic responses are quite different throughout the 
different ranges o f exercise intensity and differ if  the exercise is continuous versus 
intermittent.
Effect o f CHO ingestion on hepatic glycogenolysis and gluconeogenesis
Hepatic glycogenolysis is the primary source o f  endogenous glucose (kidneys 
contribute negligible amounts). The idea that CHO feedings delay fatigue due to a 
maintenance o f euglycemia suggests an overall reduction in glucose secretion from the 
liver—exogenous sources are able to either supplement or completely suppress 
endogenous glucose production (10, 60). Consequently, liver glycogen concentration 
remains high near the end o f  exercise, and plasma-glucose concentrations and high rates 
o f total CHO oxidation can be maintained.
In a study by Jeukendrup et al. (60), in addition to concluding that CHO feedings 
did not attenuate muscle glycogen oxidation, they also concluded that high rates o f  CHO 
ingestion can completely suppress endogenous glucose production (EGP). A primed 
continuous intravenous [6,6-2H2] glucose infusion, along with '^C-enriched ingested 
glucose allowed the investigators to determine the rates o f  appearance (Ra) and
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disappearance (Rd) from the gut. The rate o f  EGP could then be calculated as the 
difference between total Ra and gut Ra. Total endogenous CHO oxidation is a function 
o f liver and muscle glycogenolysis. Taken together, the increase in total CHO oxidation 
in the CHO trial compared to the placebo trial with the absence o f any difference in 
muscle glycogenolysis between the two trials, researchers were able to conclude that liver 
glycogenolysis was completely suppressed by CHO feedings during exercise.
Furthermore, studies conducted by Costill et al. (23) and Van Handel et al. (101) 
measured only slight increases in the glucose mass following CHO ingestion during 
moderate-intensity exercise— suggesting hepatic glycogenolysis or gluconeogenesis, or 
both, must be reduced. In fact, the authors concluded that the ingested glucose 
contributed up to two-thirds o f the circulating glucose pool. Similarly, it has been 
demonstrated that glucose infusion during moderate-intensity exercise can at least 
partially suppress endogenous glucose production in both rats (5, 110) and humans (34, 
51).
The effects o f  ingesting 500 ml/h o f a 10% CHO drink on splanchnic 
(endogenous + exogenous) glucose Ra and plasma glucose oxidation were examined in 
17, non-carbohydrate loaded, male cyclists (11). Subjects cycled for 3 hours at ~ 70% 
VOimax. The average Ra and oxidation o f endogenous glucose was significantly lower 
when subjects received the CHO versus the placebo. The authors concluded that 
ingestion o f the CHO solution resulted in either a marked liver-glycogen sparing effect or 
caused a reduction in gluconeogenesis. The exogenous source was sufficient enough to 
maintain plasma glucose concentrations.
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Oxidation of exogenous CHO
Oxidation o f exogenous CHO is affected by multiple factors: exercise intensity, 
duration, training status, muscle glycogen concentration, fed state, and perhaps even 
mode o f exercise. Direct measures and calculations o f  endogenous versus exogenous 
glucose oxidation remain difficult due to the variation in measurement techniques. 
Studies using ‘̂*C-glucose have likely underestimated the oxidation o f  exogenous 
glucose, while studies using *^C-glucose have probably overestimated it (22, 61). 
Regardless, multiple studies have been conducted in an attempt to quantify the oxidation 
of exogenous CHO and explain its interaction with other available substrates.
Exercise duration and exogenous CHO oxidation:
Ahlborg and Felig (2) had subjects cycle for 3 to 3.5 hours after a 12 hour fast. 
Analysis o f glucose changes demonstrated a 16-fold increase in leg-glucose uptake 
between minutes 40 and 90 o f exercise at ~ 60% VOimax. The increase in blood glucose 
oxidation with time is likely due, in part, to the decrease in muscle glycogenolysis as 
muscle glycogen stores become depleted. Thus late in exercise in the fasted state, when 
muscle glycogen stores are essentially depleted, blood glucose accounts for almost all 
CHO energy production (21, 26). Considering the demand the central nervous system 
(CNS) places on the endogenous glucose supply, i f  an exogenous source o f  CHO is not 
provided, muscle activity cannot be continued. Likewise, as exercise proceeds and CHO 
is ingested, exogenous CHO will contribute proportionately more to total glucose 
oxidation. A study by Couture et al. (24) examining exogenous and endogenous CHO 
oxidation during 2 hours o f treadmill running (~ 69% VOzmax) exhibited a significant
21
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
increase between 80 and 120 minutes in exogenous CHO oxidation (1.25 vs. 2.21 g/min, 
respectively). Total endogenous glucose oxidation was significantly decreased (37%) 
when exogenous glucose was oxidized.
Exercise intensity and exogenous CHO oxidation:
Exogenous CHO oxidation is also affected by the relative exercise intensity. 
During low intensity exercise (~ 30% VOzmax), CHO ingestion results in both 
hyperglycemia and hyperinsulemia—resulting in a rate o f muscle glucose uptake nearly 
twice that o f  the same intensity in the fasted state (1). However, CHO intake during 
moderate intensity exercise (50-75% VO%max) demonstrates less noticeable alterations in 
muscle glucose uptake and substrate metabolism. Pimay et al. (85, 86) reported 
exogenous CHO oxidation tended to level off between 51% and 64% of VOzmax; with 
no further increase in exogenous CHO oxidation when the intensity was increased from 
60% to 75% V02max. They concluded that exogenous glucose is largely oxidized and 
significantly contributes to the total energy supply; however, at high power outputs, the 
oxidation rate may level off or even decrease. It is believed that this leveling-off in 
muscle glucose uptake is primarily due to the suppressed insulin response compared to 
that at lower intensity levels (20, 21, 109). This is attributed to greater catecholamine 
stimulation and concurrent sympathetic nervous system (SNS) inhibition at higher 
exercise intensities (49, 99).
Training status and exogenous CHO oxidation:
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It has been noted that training state affects utilization o f exogenous CHO, After 
training, a person is less reliant on CHO metabolism (and more reliant on fat metabolism) 
at the same absolute workload. The affect o f  training on CHO metabolism at the same 
intensity relative to VOimax or VT is less clear. Most researchers agree, however, that 
with training a person becomes more tolerable o f high glucose levels and is able to more 
quickly uptake glucose into the muscle due to increased GLUT-4 content and increased 
capillarization. Training may also result in an improved ability to spare endogenous 
sources (102).
When Burelle and colleagues (15) examined glucose oxidation at rest and during 
prolonged exercise, they found that exogenous CHO was oxidized at a higher rate in 
trained versus sedentary subjects, both at rest and during exercise at the same relative and 
absolute intensities. This higher exogenous CHO oxidation rate contributed to a better 
glucose tolerance at rest and a preference for exogenous (vs. endogenous) CHO during 
exercise in trained subjects.
Another study intending to examine the affect o f training status on exogenous 
CHO oxidation found no difference, after a 6-week training intervention, in ingested 
glucose oxidation rates at rest, but documented a significant 10% increase in exogenous 
CHO oxidation rates during 90 minutes o f exercise (67). Similarly, a cross-sectional 
study by Jeukendrup (58) noted a 10% higher rate o f exogenous CHO oxidation (though 
not significant) in trained versus sedentary subjects (50 g vs. 45 g over 120 minutes).
Type o f  exercise and exogenous CHO oxidation:
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Recently it has been suggested that exogenous CHO oxidation may be affected by 
the type or mode o f exercise. It is proposed that CHO ingestion results in more marked 
elevations in blood glucose and insulin concentrations during running compared with 
cycling at the same relative exercise intensities. This difference increases muscle glucose 
uptake and exogenous CHO oxidation rates during running compared to cycling (99).
One study sought to examine the relationship between mode o f exercise and 
exogenous CHO oxidation more closely. It was determined that carbohydrate ingestion 
during running better maintained plasma glucose concentration than during cycling. 
However, CHO ingestion increased plasma glucose oxidation relative to total CHO 
oxidation in both modes (from ~23% to ~35%) (4).
Muscle glycogen content and exogenous CHO oxidation:
It has also been debated as to whether pre-exercise muscle glycogen 
concentrations affect exogenous CHO oxidation during exercise. Some studies have 
suggested that lower glycogen levels are associated with a decreased contribution o f 
exogenous CHO oxidation to the total energy expenditure (89).
In contrast to Ravussin’s study, which found no difference in the oxidation rates 
o f ingested CHO, despite exogenous CHO contributing relatively less to total energy 
production, Jeukendrup et al. (56) manipulated pre-exercise glycogen levels and found 
exogenous glucose oxidation to be 28% lower (36 g vs. 50 g) in those with low glycogen 
stores compared to those with high glycogen stores. Yet another study found exercising 
subjects to rely more on exogenous sources after consuming a low CHO diet, when
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glycogen availability is presumably low, compared to after consuming a high CHO diet 
(83).
These conflicting results are likely due to differences in exercise protocols and 
feeding strategies. It should also be noted that none o f these studies performed pre­
exercise muscle biopsies and directly measured glycogen content. Muscle glycogen 
concentration was assumed to be “high” or “low” based on dietary intake.
Limitations / bioavailability of exogenous CHO
In addition to the factors discussed above (exercise duration, intensity, type, 
training status, and muscle glycogen content), exogenous CHO oxidation can be affected 
by the type o f CHO ingested, the timing o f ingestion, and the concentration o f the liquid 
solution. Much research has also focused on the “rate limiting steps” in CHO oxidation, 
such as physiologic and metabolic factors at the muscle, intestine, or liver.
Type o f  CHO ingested:
Various types o f sugars are available to be ingested: fructose, galactose, maltose, 
sucrose, maltodextrins, and combinations o f these. Differences in the molecular structure 
affect digestion, absorption, insulin response, and the ultimate ability to be converted into 
glucose— the only form o f sugar which can enter into the muscle and undergo glycolysis 
and the energy producing pathways.
Fructose is generally more palatable and induces a smaller insulin response than 
glucose. Studies have documented about a 25% lower oxidation rate o f fructose 
compared to glucose (74, 75). For example, exogenous glucose and fructose oxidation
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rates were compared in ten untrained volunteers who exercised for 180 minutes at 45% 
VOzmax while ingesting either 150 grams o f  fructose or glucose. Glucose oxidation 
peaked at about 0.67 g/min, while fructose oxidation only peaked at 0.50 g/min. The 
lower rate o f fructose oxidation is likely due to slower absorption in the intestine and the 
necessary conversion o f fructose into glucose in the liver (61).
Hawley et al. (45) compared the oxidation o f maltose and glucose. Trained 
subjects exercised for 90 minutes at ~ 70% V02max while ingesting 180 grams o f 
glucose or maltose. Using radioactive isotopes, exogenous CHO oxidation rates were 
determined. No significant difference was found in the oxidation rates o f glucose 
compared to maltose (0.9 g/min vs 1.0 g/min, respectively). Furthermore, no differences 
were found in absorption rates o f these two sugars.
Likewise, sucrose has been found to be comparable to glucose in efficacy and 
oxidation. Moodely and colleagues (80) examined exogenous CHO oxidation rates 
during 90 minutes o f  cycling (70% VOimax) in trained subjects. Subjects ingested 
solutions o f glucose, sucrose, or glucose polymers o f various concentrations. Although 
low (likely a consequence o f the methodology), glucose and sucrose oxidation rates both 
peaked around 0,4 g/min. Higher sucrose oxidation rates, yet similar to those o f glucose, 
were observed by Wagenmakers et al. (107). During 120 minutes o f cycling at 65% 
VOimax, subjects ingested a total o f 145 grams o f sucrose in an 8% solution. The peak 
sucrose oxidation rate was estimated to be about 0.87 g/min— similar to glucose 
oxidation rates observed in other studies (56, 59, 75, 80).
Maltodextrins, or glucose polymers, are commonly used in sports drinks because 
o f their neutral taste and relatively low osmolarity (61). Oxidation rates o f maltodextrin
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have been found to be similar to those o f glucose (107). In a study where subjects 
exercised for 80 minutes at 70% V02m ax, 220 grams o f either a 17% maltodextrin or 
17% glucose solution was ingested. Oxidation was found to be similar for the glucose 
and maltodextrin drinks (42 g vs, 39 g, respectively). The peak oxidation rate for glucose 
was 0.78 g/min, which was not significantly different from maltodextrin’s peak oxidation 
rate o f 0.75 g/min (90).
Researchers have also examined the affect o f combining multiple sugar types into 
a solution. They have hypothesized that a mixture o f sugars would reduce competition 
for transport, and thus, increase total CHO absorption (62). The data suggest that it 
might, in fact, be helpful in increasing total water and CHO absorption while also 
maximizing oxidation rates. Jentjens and his colleagues have contributed a significant 
amount o f literature in this area. As discussed below, the majority o f research points to a 
maximum exogenous glucose oxidation rate o f 1.0 — 1.1 g/min; however, Jentjens et al. 
have combined sugars and recorded peak CHO oxidation rates which exceed that of 
glucose alone (52, 53, 54, 55, 108).
In one study Jentjens et al. (55) sought to compare the oxidation rates o f a 
combined glucose and sucrose solution to the oxidation rates o f an isocaloric amount o f 
glucose or sucrose alone. Subjects cycled, on five separate occasions, for 120 minutes at 
50% VOzmax, and received either 1.2 g/min o f glucose, 1.2 g/min o f sucrose (SUC), 0.6 
g/min glucose + 0.6 g/min sucrose , 1.2 g/min glucose + 1 .2  g/min sucrose , or water. 
Ultimately, the combination o f moderate amounts o f glucose and sucrose resulted in 21% 
higher oxidation rates than the oxidation rate o f  glucose alone. In a similar study 
combining glucose and finctose, average exogenous CHO oxidation rates were
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significantly higher (P<0.001) in 0.6 g/min jfructose + 1 .2  g/min glucose compared with 
both moderate (1.2 g/min) and high (1.8 g/min) rates o f  glucose ingestion alone. This 
difference represented a nearly 55% higher oxidation rate in fruc+gluc, and the 
exogenous CHO oxidation rate reached a peak o f  nearly 1.3 g/min (53). However, in a 
separate study, no difference was found in peak oxidation rates between glucose ingested 
alone compared to glucose+maltose (54).
In yet another study, members o f Jentjen’s lab examined the affect on oxidation 
rate o f  combining maltodextrin and fructose (MD+F). Again, peak oxidation rates were 
~ 40% higher when MD+F was ingested, compared to ingestion o f  MD only, and peak 
oxidation rates o f MD+F reached 1.5 g/min (108).
Finally, Jentjens et al. investigated the affect o f oxidation rates of combining 
glucose, sucrose, and fiuctose (G+S+F). Trained cyclists ingested either water (WAT), 
2.4 g/min o f  glucose (GLU), or 1.2 g/min glucose + 0.6 g/min sucrose + 0.6 g/min 
fiuctose (G+S+F), while cycling for 150 minutes at ~  62% of V02max. Peak oxidation 
rates in the G+S+F trial actually averaged 1.7 g/min—44% higher than peak oxidation 
rates o f GLU (1.18 g/min). Furthermore, researchers were able to determine endogenous 
CHO oxidation was suppressed more when G+S+F was ingested compared to GLU (52).
Maximal oxidation rate o f  ingested CHO:
Oxidation efficiency is the ratio o f the exogenous CHO oxidation rate to the 
ingestion rate (61). There is not a direct relationship between the amount o f  CHO 
ingested and its oxidation rate (e.g. if  a person doubles the amount o f CHO ingested in 
one hour, oxidation rates do not double). Issues o f practicality and gastric discomfort
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also come into play. Thus, the optimal amount o f  CHO to ingest is that which will elicit 
the greatest average oxidation rate, is most practical, and will not result in stomach pain 
or nausea.
Numerous studies have demonstrated that the maximum exogenous glucose 
oxidation rate is 1.0 to 1.1 g/min (10, 45, 59, 85), even when large amounts o f  CHO are 
ingestion (54, 55, 90, 107).
Factors limiting exogenous CHO oxidation:
There are many possible factors limiting exogenous CHO oxidation: gastric 
emptying, digestion, intestinal absorption, transport into systemic circulation, rates o f 
hepatic glucose output, and uptake by the muscle. Most evidence suggests that gastric 
emptying is generally not a major limiting factor during prolonged, moderate-intensity 
exercise (77, 80, 90). For example, in a study conducted by Massicotte et al. (77) 
subjects exercised for 120 minutes at 65% VOimax. At regular intervals, subjects 
ingested CHO either with or without metoclopramide, a drug known to stimulate gastric 
emptying. They found no significant difference in the exogenous CHO oxidation rates 
between the two trials. In other words, metoclopramide did not enhance exogenous CHO 
oxidation.
In another study, the rate o f  exogenous CHO oxidation during 90 minutes (70% 
VOzmax) o f cycling exercise was studied. Solutions o f 7.5%, 10%, or 15% were 
ingested at a rate o f  lOOmL every 10 minutes. It was found that gastric emptying actually 
decreased with increasing concentration; however, delivery to the intestine and 
exogenous CHO oxidation increased linearly with the increasing CHO concentration.
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This indicated that gastric emptying does not limit the rate o f  exogenous CHO oxidation; 
some factor subsequent to gastric emptying is regulating oxidation rate (80).
Another possible factor that could restrict exogenous CHO oxidation is the rate at 
which the glucose is taken up by the muscle. However, like gastric emptying, most 
researchers have ruled this out as the ultimate limiting factor. Studies by Jeukendrup et 
al. (59) have estimated that 90 to 95% o f the glucose appearing in the bloodstream was 
taken up and oxidized by the muscle.
The majority o f  evidence points to intestinal absorption and rate o f appearance 
into the systemic circulation as the primary factors limiting exogenous CHO oxidation.
In the Jeukendrup (59) study just mentioned, while 90 to 95% of glucose appearing in 
bloodstream was oxidized, only about one-third o f  CHO ingested appeared in the 
bloodstream. A glucose infusion study by Hawley et al. (46) provides strong evidence 
for intestinal absorption being the key factor dictating exogenous CHO oxidation rate.
He had 10 endurance-trained cyclists ride for 125 minutes at 70% VOzmax. Intestinal 
absorption and hepatic glucose uptake were bypassed by infusing glucose. Bypassing 
intestinal absorption resulted in glucose oxidation rates considerably above the “normal” 
oxidation maximum o f 1 g/min.
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Chapter 3 
Methodology 
Subjects and Setting:
Subject descriptive data is presented in Table 1. Eight well-trained males served 
as subjects for the study. Prior to all testing subjects provided written consent via a 
University Internal Review Board approved informed-consent form. All testing and trials 
took place in the Human Performance Laboratory on the University o f Montana campus 
in Missoula, MX.
Preliminary Testing:
No more than two weeks prior to the experimental exercise sessions, subjects’ 
descriptive data (percent body fat and maximal aerobic capacity) were collected. Percent 
body fat was assessed using hydrodensitometry at estimated residual volume. On 
separate days, maximal aerobic capacity was determined on both the treadmill and cycle 
ergometer using a graded exercise protocol during which subjects exercised until 
volitional exhaustion (VOzmax).
Hydrodensitometry: Subjects were fasted for at least three hours prior to the assessment 
of underwater weight using calibrated electronic scales (Exertech). They were instructed 
to complete the necessary number o f underwater weighing trials until three measurements 
within 100 grams of each other were obtained. Body density was converted to percent 
body fat using the Siri equation (93).
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Peak Aerobic Capacity (Treadmill): Subjects were fasted for at least three hours prior to 
initiating the test. After a 10 to 15 minute walking warm-up on the treadmill (Quinton 
Q65, Seattle, WA), the protocol was initiated at 106.8 m-min ' (4 mile hr'*), 0% grade. 
The percent grade was increased 1% every 30 seconds until a 20% grade was achieved, 
after which treadmill speed was increased to 133.8 m-min‘* (5 mile-hr'*) and progressed 
13.38 m-min'^ (0.5 mile hr'^) every 30 seconds thereafter until volitional exhaustion 
(VOzmax) . Subjects received verbal encouragement throughout the test. Expired gases 
were continuously monitored using a calibrated metabolic system (Parvomedics, Inc., 
Salt Lake City, UT).
Peak Aerobic Capacity (Cycle Ergometer): Subjects were fasted for no less than three 
hours prior to the test. After a 10 to 15 minute warm-up at 75 watts on an electronically- 
braked cycle ergometer (Velotron, Seattle, WA), the protocol was initiated at 0 watts and 
progressed at a rate o f 30 watts min"  ̂ (ramp protocol) until volitional exhaustion 
(VOzmax). Subjects received verbal encouragement throughout the test. Expired gases 
were continuously monitored using a calibrated metabolic system (Parvomedics, Inc., 
Salt Lake City, UT).
Ventilatory Threshold and Intensity Determination: Metabolic gas measurements fi’om 
each maximal exercise test were analyzed to estimate ventilatory threshold (Tvent) for 
cycle and treadmill activity. Ventilatory threshold was determined by a combination of 
three methods: the ventilatory equivalent method, the excess CO2 method, and the V- 
slope method according to previously described methodology (37). The exercise
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intensity at Tvent for each mode o f activity was independently selected by two 
investigators and then compared. The agreed upon Tvent was used to quantify the 
percent-grade (treadmill) and power output in watts (cycle ergometer) to establish the 
exercise intensities for the 8-hr trials (70, 90, 100, 110% of Tvent). The average 
workloads on the cycle ergometer and treadmill are depicted in Table 2. Each subject’s 
respective workloads were programmed into a computer so that wattage (cycle- 
ergometer) and percent-grade (treadmill) were automatically adjusted during the exercise 
trials.
Diet and Activity Specifications: Each subject received dietary instructions for the 24- 
hour period prior to each 8-hour exercise session. Subjects were prescribed a diet 
providing 5 g-kg body weight'* carbohydrate and 1,2 g kg body weight'* protein. The 
basic diet was developed as a minimum and subjects were asked to record additional food 
items eaten and to match their diet on the days prior to both 8-hour exercise trials.
Subjects were also instructed to maintain their regular exercise/training regimen between 
the preliminary testing and completion of the second trial. However, they were asked to 
abstain from any strenuous activity for the 24 hours prior to each 8-hour trial.
Experimental Trials:
The order o f the two 8-hour exercise sessions was randomized and completed in a 
double-blind crossover design, with no less than 7 days between trials. Following a 12- 
hour fast, subjects reported to the lab at 0615, Upon arrival, subjects were fitted with a 
chest strap heart-rate monitor and allowed to rest for a period o f 10 minutes, after which a
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20-mL blood sample was obtained (venopuncture). The blood-handling procedures are 
described later. A muscle biopsy was obtained from the vastus lateralis under local 
anesthetic (1% lidocaine). An incision was made through the skin and muscle fascia 
approximately 12-16 cm proximal to the patella, and a Bergstrom biopsy needle was 
inserted vertically through the incision into the vastus lateralis. Fresh muscle samples 
were separated into 25-50 mg sections, placed in cryovials and immediately frozen in 
liquid nitrogen. At 0715 subjects were provided with a small, standardized breakfast 
amounting to 3223 kJ (770 kcal), 139 g CHO, 13 g fat, and 23 g protein (PowerBar®, 
One-Choice nutrition drink, blueberry bagel).
At approximately 0750 subjects were asked to void their bladder and a nude body 
weight was recorded. Each 8-hour exercise session started at 0800. The exercise 
protocol is described below. During the Placebo Trial (PLA), subjects consumed 150 ml 
o f an artificially sweetened drink every 15 minutes (minutes 0, 15, 30, 45 o f each hour). 
During the Carbohydrate Trial (CHO), subjects consumed 60 g CHO hr^ (1003 kJ; 240 
kcal) provided in 150 ml o f a 10% maltodexdrin solution every 15 minutes, as during the 
PLA trial.
After the completion o f hour 4, subjects were given a 35-minute rest period. 
During this time a second 20-mL blood sample was obtained. Subjects were then 
provided with a small standardized lunch providing 3600 kJ (860 kcal), 111 g CHO, 30 g 
fat, and 36 g protein (Lunchable®, PowerBar®, One-Choice nutrition drink). The final 4 
hours o f exercise began at 1230.
During hours 1, 4, 5, and 8 metabolic gases were collected during the last 7 
minutes on each exercise mode, using the same calibrated metabolic system described
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earlier (Parvomedics, Inc., Salt Lake City, UT). Upon completion o f the 8* hour of 
exercise the subject was assisted to a bed, a final 20-mL blood sample was obtained, and 
the subject was prepped for the post-exercise muscle biopsy. The post-exercise biopsy 
was obtained from a second incision made approximately 2-2.5 cm proximal to the initial 
biopsy site.
Exercise protocol: The hour sessions started with 25 minutes o f cycling on the same 
electronically-braked cycle ergometer (Velotron, Seattle, WA) used during the 
preliminary maximal exercise test. Upon completion o f the 25 minutes o f cycling, 
subjects were provided with a 5-minute rest period to allow for changing o f shoes and/or 
use o f the lavatory prior to transitioning to the treadmill. The 25 minutes o f treadmill 
walking were performed on the same motorized treadmill (Quinton Q65, Seattle, WA) 
used during the preliminary maximal exercise test. After completing the 25 minutes o f 
exercise on the treadmill, subjects were again provided with a 5-minute rest period to 
allow for changing o f shoes and/or use o f the lavatory prior to transitioning back to the 
cycle ergometer. Cycling and treadmill walking were repeated for the 8-hour periods. 
Figure 1 depicts the 25-minute intensity breakdown for each mode o f exercise.
1 2  a
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The exercise was initiated with six minutes of cycling/walking at 70% Tvent, followed by 
a sequence o f three, two-minute intervals completed at 110, 100, and 90% Tvent, 
respectively. Each interval was followed by one-minute at 70% Tvent. The remaining 
10 minutes o f  exercise were completed at 70% Tvent.
Procedures
Metabolic Gas Collection: Metabolic gases were collected during 70% Tvent exercise 
throughout the 8-hour exercise session during the time points previously specified. The 
steady-state values VO2 and VCO2 measurements were used to calculate whole-body 
carbohydrate and fat oxidation (36).
Heart Rate and RPE: Heart rate (HR) was continuously monitored and minute averages 
were recorded via a chest-strap transmitter and a receiver (Polar). The data was later 
downloaded and imported into an Excel spreadsheet for analysis. The average heart rate 
during the last minute o f the 110% Tvent interval and the average heart rate during the 
last five minutes at 70% Tvent are reported. RPE was recorded during hours 1, 4, 5, and 
8 on both modes of exercise at each intensity. During the last minute of each interval 
(minutes 7, 10, and 13) and minute 22 (70% Tvent), subjects were instructed to look at 
the 6-20 Borg RPE scale and respond with how hard they felt they were working overall.
Blood Samples: Each o f the three blood samples (pre, mid, and post 8-hours) were 
collected from an anticubital vein into four 5-mL Vacutainer vials (20-mL each 
collection). The samples remained at room temperature for 15 minutes, after which, they
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were centrifuged at 4000 revmin'*, 4°C for 10 minutes. Serum was separated into 
designated cryovials and frozen at -80°C until subsequent analysis o f glucose, insulin, 
and lactate concentrations.
Glucose, Insulin, and Lactate Analysis'. Blood samples for glucose were analyzed in 
duplicate using an enzymatic spectrophotometric method (Infinity glucose (HK) liquid 
stable reagent, ThermoTrace Ltd.). Blood samples for insulin were analyzed in duplicate 
using an enzymatic spectrophotometric Elisa method (EIA2935, DRG International). 
Similarly, samples for lactate were analyzed in duplicate using an enzymatic 
spectrophotometric method (71).
Muscle Glycogen Analysis: Muscle tissue samples for glycogen concentration were 
analyzed using an enzymatic spectrophotometric method (Infinity glucose (HK) liquid 
stable reagent, ThermoTrace Ltd.). Upon removal from the -80°C freezer 20-25 pg 
samples were weighed and homogenized in 1 mL o f a 1 N HCL solution using a manual 
mortar and pestle tissue grinder. Ground samples were incubated for three hours at 
95.6°C. After incubation, the pH was normalized by adding 0.5 mL of 1 N NaOH to 0.5 
mL o f boiled tissue sample. Samples were analyzed in triplicate against known glycogen 
and glucose controls as previously described (92).
Research Design and Statistical Analyses
Urinary nitrogen and changes in body weight were analyzed using dependent t- 
tests. All other variables were compared using 2-way repeated-measures ANOVA using
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a series o f a-priori planned comparisons. Statistical significance was set at p<0.05. All 
values are reported as means ± SD.
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ABSTRACT
PU RPO SE: The purpose o f  this study was to examine the effects o f exogenous 
carbohydrate intake during eight hours o f prolonged exercise on muscle glycogenolysis 
and whole-body substrate oxidation. M ETHODS: Eight well-trained males participated 
in two 8-hour exercise trials. During each hour, subjects repeated 25 minutes cycle 
ergometer exercise, 5 minutes rest, 25 minutes treadmill exercise, and 5 minutes rest. 
Each 25 minute exercise segment consisted o f two steady state and three interval work 
bouts. Muscle biopsies were obtained pre- and post-exercise. Blood samples were 
collected pre-exercise, after hour 4, and post-exercise. Metabolic gases were collected 
during hours 1,4, 5, and 8. Every 15 minutes, subjects ingested 150 mL of either a 10% 
carbohydrate solution (CHO) or a sweetened placebo (PLA). Subjects were provided 
with a standardized breakfast and lunch. Data were analyzed using repeated-measures 
ANOVA and statistical significance was set at p<0.05. RESULTS: There was a 
significant difference in the rate o f muscle glycogenolysis between trials (9.4 ±2.1 and
13.7 ± 4.6 mmol kg wet wt.‘*hr'’ for CHO and PLA, respectively). Rates o f whole-body 
carbohydrate oxidation demonstrated a general maintenance throughout exercise for the 
CHO trial but showed a decline throughout the PLA trial. Blood glucose and insulin 
were higher for CHO after hour 4 and post exercise compared to PLA. CONCLUSION: 
The results from this study suggest that regular exogenous carbohydrate feedings during 
prolonged, intermittent exercise attenuate muscle glycogenolysis while maintaining 
plasma glucose and insulin concentrations and rates o f whole-body carbohydrate 
oxidation.
KEY W ORDS: substrate oxidation, muscle glycogenolysis, prolonged exercise
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INTRODUCTION
Paragraph I: The fatigue-delaying and performance-enhancing effects o f carbohydrate 
(CHO) supplementation during physical work and exercise have consistently been 
demonstrated (4, 18, 26). While the improved work-capacity and performance benefits 
of ingesting CHO during exercise appear conclusive, the mechanism underlying this 
phenomenon remains unclear. While some researchers have suggested that fatigue is 
postponed due to the preservation o f muscle glycogen (2, 6, 25, 30), others contend that it 
is due to maintenance o f euglycemia (1, 4, 12), while others suggest a central fatigue 
mechanism (3, 22). Most likely, all three o f these factors contribute to the complex event 
o f overall fatigue during prolonged muscular work. The combination of these proposed 
mechanisms may depend on other factors such as the mode and intensity o f exercise, 
amount, type, and timing o f CHO ingestion, pre-exercise nutritional and training status, 
as well as psychological factors such as motivation and boredom. Additionally, most 
research has examined only moderate to high intensity exercise performed for four or less 
hours (12, 20, 25,26, 27). It cannot be assumed that whole-body and muscle metabolism 
are similar during exercise lasting up to 4 hours compared to exercise lasting much 
longer.
Paragraph 2: In the fasted state, muscle glycogen provides a majority of the total CHO 
oxidized during moderate-high intensity exercise. However, it has been demonstrated 
that CHO feedings could reduce muscle glycogen depletion during exercise (11), and that 
this reduced muscle glycogenolysis is associated with a delayed time to fatigue. Some 
researchers contend this sparing o f muscle glycogen occurs primarily in type I fibers (25,
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26, 28, 30), which may become glycogen depleted after only 60 minutes o f low  intensity 
exercise (28), and the selective depletion o f these fibers is slower when exogenous CHO 
is provided (25, 26). It has also been shown that time trial performance is improved after 
carbohydrate loading, despite no differences in end muscle glycogen concentrations (21). 
This suggests that the underlying rate o f CHO oxidation may play a role in the regulation 
o f pace during extended exercise, while the absolute glycogen concentration may 
determine the point o f fatigue. Therefore, regardless o f the combined causes o f fatigue, 
muscle glycogen is clearly essential as an energy substrate, which suggests regular 
carbohydrate supplementation may be even more critical during prolonged activities (i.e. 
lasting longer than four hours). Furthermore, in conjunction with a reduction in muscle 
glycogenolysis, exogenous CHO may also maintain rates o f whole-body CHO oxidation 
rates (13, 14), which is critical if a work rate is expected to be sustained. Thus, while 
previous research has contributed significantly to our current knowledge o f CHO 
metabolism during shorter duration, higher intensity exercise, more research is necessary 
to explain substrate utilization and muscle glycogenolysis during extended sport and 
work lasting longer than four hours.
Paragraph 3: The purpose o f this study was to determine the effects of carbohydrate 
supplementation on whole-body substrate oxidation and muscle glycogenolysis during 
eight hours o f intermittent, moderate-intensity exercise interspersed with higher intensity 
intervals. This protocol was designed to simulate real-life extended work patterns. We 
hypothesized that whole-body carbohydrate oxidation would be better maintained during
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the CHO trial compared to the placebo trial and that the oxidation o f muscle glycogen 
would be lower during the CHO trial compared to the placebo trial.
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METHODS 
Subjects and Setting:
Paragraph 4: Subject descriptive data is presented in Table 1. Eight well-trained males 
served as subjects for the study. Prior to all testing subjects provided written consent via 
a University Internal Review Board approved informed-consent form. All testing and 
trials took place in the Human Performance Laboratory on the University o f Montana 
campus in Missoula, MT.
(Suggest Table 1 here)
Preliminary Testing:
F ara^aph  5: No more than two weeks prior to the experimental exercise sessions, 
subjects’ descriptive data (percent body fat and maximal aerobic capacity) were 
collected. Percent body fat was assessed using hydrodensitometry at estimated residual 
volume. On separate days, maximal aerobic capacity was determined on both the 
treadmill and cycle ergometer using a graded exercise protocol during which subjects 
exercised until volitional exhaustion (V0 2 max).
Paragraph 6: Hydrodensitometry: Subjects were fasted for at least three hours prior to 
the assessment of underwater weight using calibrated electronic scales (Exertech). They 
were instructed to complete the necessary number o f underwater weighing trials until 
three measurements within 100 grams o f each other were obtained. Body density was 
converted to percent body fat using the Siri equation (24).
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Paragraph 7: Peak Aerobic Capacity (Treadmill): Subjects were fasted for at least three 
hours prior to initiating the test. After a 10 to 15 minute walking warm-up on the 
treadmill (Quinton Q65, Seattle, WA), the protocol was initiated at 106.8 m-min'* (4 
mile hr'*), 0% grade. The percent grade was increased 1% every 30 seconds until a 20% 
grade was achieved, after which treadmill speed was increased to 133.8 m-min'^ (5 
mile hr'*) and progressed 13.38 m min'^ (0.5 mile hr'^) every 30 seconds thereafter until 
volitional exhaustion (VOimax) . Subjects received verbal encouragement throughout 
the test. Expired gases were continuously monitored using a calibrated metabolic system 
(Parvomedics, Inc., Salt Lake City, UT).
Paragraph 8: Peak Aerobic Capacity (Cycle Ergometer): Subjects were fasted for no 
less than three hours prior to the test. After a 10 to 15 minute warm-up at 75 watts on an 
electronically-braked cycle ergometer (Velotron, Seattle, WA), the protocol was initiated 
at 0 watts and progressed at a rate o f  30 watts min'^ (ramp protocol) until volitional 
exhaustion (VOimax). Subjects received verbal encouragement throughout the test. 
Expired gases were continuously monitored using a calibrated metabolic system 
(Parvomedics, Inc., Salt Lake City, UT).
Paragraph 9: Ventilatory Threshold and Intensity Determination: Metabolic gas 
measurements from each maximal exercise test were analyzed to estimate ventilatory 
threshold (Tvent) for cycle and treadmill activity. Ventilatory threshold was determined 
by a  combination of three methods: the ventilatory equivalent method, the excess CO2 
method, and the V-slope method according to previously described methodology (10).
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The exercise intensity at Tvent for each mode o f activity was independently selected by 
two investigators and then compared. The agreed upon Tvent was used to quantify the 
percent-grade (treadmill) and power output in watts (cycle ergometer) to establish the 
exercise intensities for the 8-hr trials (70, 90,100, 110% o f Tvent). The average 
workloads on the cycle ergometer and treadmill are depicted in Table 2. Each subject’s 
respective workloads were progranuned into a computer so that wattage (cycle- 
ergometer) and percent-grade (treadmill) were automatically adjusted during the exercise 
trials.
(Suggest Table 2 here)
Paragraph 10: Diet and Activity Specifications: Each subject received dietary 
instructions for the 24-hour period prior to each 8-hour exercise session. Subjects were 
prescribed a diet providing 5 g kg body weight"* carbohydrate and 1.2 g kg body weight"* 
protein. The basic diet was developed as a minimum and subjects were asked to record 
additional food items eaten and to match their diet on the days prior to both 8-hour 
exercise trials. Subjects were also instructed to maintain their regular exercise/training 
regimen between the preliminary testing and completion o f the second trial. However, 
they were asked to abstain from any strenuous activity for the 24 hours prior to each 8- 
hour trial.
Experimental Trials:
Paragraph 11: The order o f  the two 8-hour exercise sessions was randomized and 
completed in a  double-blind crossover design, with no less than 7 days between trials.
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Following a 12-hour fast, subjects reported to the lab at 0615. Upon arrival, subjects 
were fitted with a chest strap heart-rate monitor and allowed to rest for a period o f 10 
minutes, after which a 20-mL blood sample was obtained (venopuncture). The blood- 
handling procedures are described later. A muscle biopsy was obtained from the vastus 
lateralis under local anesthetic (1% lidocaine). An incision was made through the skin 
and muscle fascia approximately 12-16 cm proximal to the patella, and a Bergstrom 
biopsy needle was inserted vertically through the incision into the vastus lateralis. Fresh 
muscle samples were separated into 25-50 mg sections, placed in cryovials and 
immediately frozen in liquid nitrogen. At 0715 subjects were provided with a small, 
standardized breakfast amounting to 3223 kJ (770 kcal), 139 g CHO, 13 g fat, and 23 g 
protein (PowerBar®, One-Choice nutrition drink, blueberry bagel).
Paragraph 12: At approximately 0750 subjects were asked to void their bladder and a 
nude body weight was recorded. Each 8-hour exercise session started at 0800. The 
exercise protocol is described below. During the Placebo Trial (PLA), subjects 
consumed 150 ml o f an artificially sweetened drink every 15 minutes (minutes 0, 15, 30, 
45 o f each hour). During the Carbohydrate Trial (CHO), subjects consumed 60 g 
CHO-hr'^ (1003 kJ; 240 kcal) provided in 150 ml o f a 10% maltodexdrin solution every 
15 minutes, as during the PLA trial.
Paragraph 13: After the completion o f hour 4, subjects were given a 35-minute rest 
period. During this time a second 20-mL blood sample was obtained. Subjects were then 
provided with a small standardized lunch providing 3600 kJ (860 kcal), 111 g CHO, 30 g
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fat, and 36 g protein (Lunchable , PowerBar , One-Choice nutrition drink). The final 4 
hours o f  exercise began at 1230.
Paragraph 14: During hours 1, 4, 5, and 8 metabolic gases were collected during the last 
7 minutes on each exercise mode, using the same calibrated metabolic system described 
earlier (Parvomedics, Inc., Salt Lake City, UT). Upon completion o f the 8^ hour of 
exercise the subject was assisted to a bed, a final 20-mL blood sample was obtained, and 
the subject was prepped for the post-exercise muscle biopsy. The post-exercise biopsy 
was obtained from a second incision made approximately 2-2.5 cm proximal to the initial 
biopsy site.
Exercise protocol:
Paragraph 15: The hour sessions started with 25 minutes o f cycling on the same 
electronically-braked cycle ergometer (Velotron, Seattle, WA) used during the 
preliminary maximal exercise test. Upon completion o f the 25 minutes o f cycling, 
subjects were provided with a 5-minute rest period to allow for changing o f shoes and/or 
use o f the lavatory prior to transitioning to the treadmill. The 25 minutes o f treadmill 
walking were performed on the same motorized treadmill (Quinton Q65, Seattle, WA) 
used during the preliminary maximal exercise test. After completing the 25 minutes of 
exercise on the treadmill, subjects were again provided with a 5-minute rest period to 
allow for changing o f shoes and/or use o f the lavatory prior to transitioning back to the 
cycle ergometer. Cycling and treadmill walking were repeated for the 8-hour periods. 
Figure 1 depicts the 25-minute intensity breakdown for each mode of exercise.
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(Suggest Figure 1 here)
The exercise was initiated with six minutes o f cycling/walking at 70% Tvent, followed by 
a sequence o f three, two-minute intervals completed at 110, 100, and 90% Tvent, 
respectively. Each interval was followed by one-minute at 70% Tvent. The remaining 
10 minutes o f exercise were completed at 70% Tvent.
Paragraph 16: Metabolic Gas Collection: Metabolic gases were collected during 70% 
Tvent exercise throughout the 8-hour exercise session during the time points previously 
specified. The steady-state values VO2 and VCO2 measurements were used to calculate 
whole-body carbohydrate and fat oxidation (9).
Paragraph 17: Heart Rate and RPE: Heart rate (HR) was continuously monitored and 
minute averages were recorded via a chest-strap transmitter and a receiver (Polar). The 
data was later downloaded and imported into an Excel spreadsheet for analysis. The 
average heart rate during the last minute o f the 110% Tvent interval and the average heart 
rate during the last five minutes at 70% Tvent are reported. RPE was recorded during 
hours 1, 4, 5, and 8 on both modes of exercise at each intensity. During the last minute of 
each interval (minutes 7, 10, and 13) and minute 22 (70% Tvent), subjects were 
instructed to look at the 6-20 Borg RPE scale and respond with how hard they felt they 
were working overall.
Paragraph 18: Blood Samples: Each o f the three blood samples (pre, mid, and post 8- 
hours) were collected from an anticubital vein into four 5-mL Vacutainer vials (20-mL
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each collection). The samples remained at room temperature for 15 minutes, after which, 
they were centrifuged at 4000 rev min"% 4°C for 10 minutes. Serum was separated into 
designated cryovials and frozen at -80°C until subsequent analysis o f glucose, insulin, 
and lactate concentrations.
Paragraph 19: Glucose, Insulin, and Lactate Analysis: Blood samples for glucose were 
analyzed in duplicate using an enzymatic spectrophotometric method (Infinity glucose 
(HK) liquid stable reagent, ThermoTrace Ltd.). Blood samples for insulin were analyzed 
in duplicate using an enzymatic spectrophotometric Elisa method (EIA2935, DRG 
International). Similarly, samples for lactate were analyzed in duplicate using an 
enzymatic spectrophotometric method (17).
Paragraph 20: Muscle Glycogen Analysis: Muscle tissue samples for glycogen 
concentration were analyzed using an enzymatic spectrophotometric method (Infinity 
glucose (HK) liquid stable reagent, ThermoTrace Ltd.). Upon removal from the -80°C 
freezer 20-25 (ig samples were weighed and homogenized in 1 mL of a 1 N HCL solution 
using a manual mortar and pestle tissue grinder. Ground samples were incubated for 
three hours at 95.6°C. After incubation, the pH was normalized by adding 0.5 mL of 1 N 
NaOH to 0.5 mL o f boiled tissue sample. Samples were analyzed in triplicate against 
known glycogen and glucose controls as previously described (23).
Paragraph 21: Research Design and Statistical Analyses: Change in body weight was 
analyzed using dependent t-tests. All other variables were compared using 2-way
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repeated-measures ANOVA using a series o f a-priori planned comparisons. Statistical 
significance was set at p<0,05. All values are reported as means ± SD.
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RESULTS
Paragraph 22: Body weight decreased across both trials, but there was no significant 
difference between trials (A CHO = -1.7 ± 1.0; A PLA = - 2.1 ± 0,8; p<0.05). Self­
selected cycling cadence was not significantly different between the CHO and PLA trials 
(80.2 ± 9.8 and 80.7 ± 12.4 revmin*’ for CHO and PLA, respectively; p<0.05).
Heart Rate
Paragraph 23: The average heart rate during 70% Tvent and 110% Tvent were not 
significantly different between trials on either the cycle-ergometer or the treadmill 
(p<0.05). However, during both trials heart rate increased across time for each mode and 
workload. Data are presented in Tables 3a and 3b.
Rates of Perceived Exertion
Paragraph 24: There were no signficant differences between CHO and PLA in RPE at 
any time point for either the cycle ergometer or treadmill (p<0.05). RPE increased across 
time for each mode and workload. Data are presented in Tables 4a and 4b.
Blood Markers
Paragraph 25: Lactate: There were no significant differences between trials in the pre-, 
mid-, and post-exercise lactate concentrations (p<0.05). The overall average lactate 
concentration during CHO was lower than the overall average lactate concentration 
throughout PLA (1.83 ± 0.42; 2.14 ± 0.77 mmol L for CHO and PLA, respectively; 
p<0.05). The average post-exercise lactate concentration of both trials was higher than
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the average pre-exercise lactate concentration o f both trials (1.70 ± 0.40; 2.30 ± 0.69 
mmol L for pre and post, respectively; p<0.05). Blood lactate concentrations are 
presented in Figure 2.
Paragraph 26: Glucose: Blood glucose concentrations were significantly higher during 
the CHO trial at mid- and post-exercise compared to the placebo trial (p<0.05). During 
the CHO trial, plasma glucose concentrations were significantly higher mid- and post­
exercise compared to pre-exercise (p<0.05). In contrast, during the placebo trial, the 
plasma glucose concentrations were significantly lower post-exercise compared to pre­
exercise (p<0.05). Blood glucose concentrations are presented in Figure 3.
Paragraph 27: Insulin: Insulin concentrations were significantly higher during the CHO 
trial at mid- and post-exercise compared to PLA (p<0.05). During the CHO trial, insulin 
concentrations were significantly increased mid- and post-exercise compared to pre- 
exercise (p<0.05). In contrast, during the placebo trial, the insulin concentration was 
significantly lower post-exercise compared to pre-exercise (p<0.05). Insulin 
concentrations are presented in Figure 4.
Substrate oxidation
Paragraph 28: Carbohydrate oxidation: The calculated rates o f whole-body 
carbohydrate oxidation during both cycle and treadmill exercise were significantly higher 
during CHO compared to PLA for all hours o f measurement after hour 1 (p<0.05).
Within the placebo trial, hours 4, 5, and 8 all exhibited significantly lower rates of CHO
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oxidation compared to hour 1 (p<0.05). In contrast, there were no differences in CHO 
oxidation across time during the CHO trial, except during hour 8 o f treadmill exercise 
where there was a small decline (p<0.05). (See Figure 5a and 5b).
Paragraph 29: Fat oxidation: The calculated rates of whole-body fat oxidation during 
both cycle and treadmill exercise were significantly lower during CHO compared to PLA 
for all hours o f measurement after hour 1 (p<0.05). During PLA, fat oxidation was 
significantly elevated above hour 1 at hours 4, 5, and 8 (p<0.05). During CHO, fat 
oxidation was significantly lower at hour 5 compared to hour 1 during cycling, but not 
during treadmill exercise, and significantly higher at hour 8 compared to hour 1 for both 
the cycle and treadmill (p<0.05). (See Figure 6a and 6b).
Muscle Glycogenolysis
Paragraph 30: Both CHO and PLA demonstrated a significant decrease in muscle 
glycogen concentration across the 8-hour exercise trial (p<0.05). There were no 
significant differences between CHO and PLA in the pre-exercise muscle glycogen 
concentrations. However, post-exercise muscle glycogen values were significantly lower 
for PLA compared to CHO (p<0.05) (Figure 7). The calculated rate o f muscle 
glycogenolysis was significantly lower for CHO vs. PLA (9.4 ±  2.1 and 13.7 ± 4.6 
mmol kg wet wt.'^-hr'*, respectively; p<0.05).
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DISCUSSION
Paragraph 31: The effects o f CHO supplementation on muscle metabolism and substrate 
oxidation have not been thoroughly investigated during physical activities lasting longer 
than four hours. This study presents a unique opportunity to examine whole-body 
metabolism and muscle glycogenolysis during prolonged, varied-intensity exercise. The 
premise behind this investigation was to simulate a physical work day under controlled 
laboratory conditions. Thus, the intensity was set relative to each individual’s Tvent, the 
routine was interspersed with high and low intensity work bouts, different modes of 
activity were employed, and short rest periods were provided—the primary criteria 
ultimately characterizing how an individual works in the field. We investigated whether 
an exogenous CHO source would alter muscle glycogenolysis during the course o f eight 
hours o f exercise. Prior research has demonstrated that CHO supplementation improves 
performance (4, 15, 18, 26) and may decrease muscle glycogen utilization during shorter, 
steady-paced activities (2, 6, 25, 30). The results o f this study provide evidence that 
these same responses occur during longer, varied-intensity activities with short rest 
periods.
Paragraph 32: In the present investigation an average o f 1 g min * of exogenous CHO 
was provided and was sufficient enough to maintain whole-body CHO oxidation rates 
throughout much of the day—averaging 1.97 ± 0.39 g-min'* across the day and peaking at
2.07 ±0 .17  g-min’* in hour 5 (following lunch) during cycling exercise. These values are 
similar to those of Jeukendrup et al. who provided 1.5 g-min*‘ o f exogenous CHO and 
observed average total CHO oxidation rates of approximately 2 g-min*  ̂over 5 hours of
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exercise (15). Jeukendrup et al.’s subjects exercised at an average o f 58% V02max, as 
compared to the current study in which subjects averaged 50% VO^max during the 70% 
Tvent, steady-state segments. The slightly higher values o f CHO oxidation rates found 
by Jeukendrup et al. are probably due to the higher exercise intensity. Importantly, 
exogenous CHO supplied at 1 to 1.5 g-min** was sufficient to maintain whole-body CHO 
oxidation over the duration o f both studies.
Paragraph 33: During the treadmill portion o f the exercise trial, rates of whole-body 
CHO oxidation averaged 1.92 ± 0.31 g-min‘* during hours 1, 4, and 5, but dropped to
1.70 ± 0.43 g-min^ during the final hour. Unlike the cycle, total CHO oxidation on the 
treadmill was not maintained throughout the entire 8 hours o f exercise, showing a slight, 
but significant, drop during the last collection period. This may indicate a mode specific 
difference in the metabolic responses to exogenous CHO ingestion, as has been 
previously suggested (1, 5) or it may be a function o f time, since treadmill walking 
followed cycling. However, over the course o f eight hours o f exercise, it is not likely that 
an additional 25 minutes o f treadmill walking provides the complete explanation for the 
significant drop in CHO oxidation.
Paragraph 34: The most significant finding from this study is the decreased rate of 
muscle glycogenolysis when CHO was supplemented at 60 g hr ' (1 g-min'*) for 8 hours 
compared to a placebo solution. This, in combination with the overall maintenance of 
whole-body CHO oxidation, indicates a sparing o f muscle glycogen with a concomitant 
increased reliance on exogenous CHO sources as the exercise proceeds. These findings
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agree with those from previous research which has documented a reduced dependency on 
muscle glycogen stores as exercise continues and an exogenous source o f CHO is 
provided (2, 6, 11, 25, 26, 30). Yaspelkis et al. (30) demonstrated that after 190 minutes 
o f variable-intensity exercise, muscle glycogen concentrations were better maintained 
when subjects were fed CHO versus a placebo. Moreover, subsequent time to exhaustion 
averaged 25 minutes longer during the CHO trial— indicating a slower rate o f muscle 
glycogenolysis and a reduced dependency on muscle glycogen during the previous 190 
minutes o f  exercise. Despite the duration o f our exercise trials being much longer, our 
data agrees with that o f Yaspelkis et al. and demonstrates the potential glycogen sparing 
effects o f exogenous CHO when the exercise is prolonged, the intensity is varied, and 
short rest periods are provided.
Paragraph 35: During the PLA trial, the rate o f muscle glycogenolysis was 
approximately 45% higher compared to the CHO trial, while the rates of whole-body 
CHO oxidation (during cycling) were 26, 20 and 63% lower at hours 4, 5, and 8, 
respectively. Similarly, the rates o f whole-body CHO oxidation during the treadmill 
portion o f the exercise were 36, 32, and 89% lower during the PLA trial for hours 4, 5, 
and 8, respectively. These data clearly demonstrate that exogenous CHO was the primary 
substrate contributing to whole-body CHO oxidation, and while muscle glycogenolysis 
was greatly attentuated by CHO supplementation, the effects on whole-body CHO 
oxidation were more predominant.
67
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Paragraph 36: The influence on blood glucose concentrations by exogenous CHO 
across these long trials was another important result. Not only was blood glucose 
maintained, but it rose significantly compared to pre-exercise values throughout the CHO 
trial. These results are in contrast to previous research (4, 12, 19) which was specifically 
designed to determine if  postponement o f fatigue was due to muscle glycogen sparing or 
maintenance o f euglycemia. Since our exercise and feeding protocols are different fi-om 
these studies, direct comparisons cannot be made; however, the subjects in the prior 
studies did not exhibit a difference in muscle glycogen utilization. The major 
contributing difference between our study and those mentioned is likely the lower 
intensity o f our exercise (~50% V02m ax vs. ~70% V02m ax in the other studies). In our 
study, the significant increase in blood glucose concentrations, in combination with the 
decreased rate o f muscle glycogenolysis, again suggests that perhaps a feeding strategy 
which provides at least 60 g CHO hr^ may not only maintain euglycemia, but also 
maintain total CHO oxidation with less reliance on muscle glycogen stores during 
extended, varied-intensity exercise.
Paragraph 37: Since the rate o f endogenous CHO oxidation (Ra and Rd glucose) was 
not measured in the current study, whether or not the exogenous source o f glucose 
completely suppressed hepatic glycogenolysis cannot be ascertained. However, 
considering both trials were performed following a 12-hour fast, and the breakfast and 
lunch only provided about 6823 kJ (1630 kcal), it is a reasonable assumption that the 
contribution fi-om hepatic glycogen was similar between trials and was not a major 
contributor to the overal difference in oxidized CHO. Furthermore, the maintenance of
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total CHO oxidation in conjunction with the decreased rate o f muscle glycogenolysis 
during the CHO trial, suggests exogenous CHO alone may have maintained whole-body 
CHO oxidation during the later hours o f exercise. Future research should aim to 
investigate the endogenous glucose response to long-duration, varied-intensity activity. 
However, the nature o f stable isotopic tracer infusion methodology presents difficulties 
during work bouts o f this duration and those difficulties will need to be addressed in 
order to investigate glucose kinetics during prolonged work.
Paragraph 38: The insulin response in our study paralled the changes in blood 
glucose— demonstrating a significant rise throughout the 8-hour work period during the 
CHO trial. Interestingly, the blood glucose and insulin response in this study are in 
contrast to the findings from other studies in which values tended to peak around 30 
minutes into exercise and then steadily decline (8, 12, 26). This difference is most likely 
due to the lower exercise intensity required for the extended duration o f our trials. Lower 
intensity exercise elicits a more pronounced insulin response than higher intensity 
exercise (4, 12, 19), thereby increasing glucose uptake, especially during rest periods. 
Most prior studies have examined exercise performed at higher intensities, which tends to 
blunt the insulin response. Furthermore, it has been suggested that both a hyperglycemic 
and hyperinsulimic response are necessary in order to reduce muscle glycogen utilization 
(30). Our blood glucose and insulin data do agree with those o f Yaspelkis et al. (30) in 
the study described earlier. They reported a marked elevation o f both blood glucose (up 
to 2.5 mmol L '' above control levels) and plasma insulin levels (up to 3.5 times the 
values observed in the control trial)— accompanied by a 30% reduction in muscle
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glycogenolysis when cycling at intensities varying between 45% and 75% VOzmax. 
These observed physiological changes are likely a combination o f the lower exercise 
intensity and the intermittent nature o f our extended work-bout design.
Paragraph 39: It has been reported that varied-intensity exercise or even short breaks in 
muscle work will allow for significant glucose uptake and possible short-term glycogen 
resynthesis (11,16). In addition, contractile activity and insulin act synergistically to 
increase glucose uptake by the working muscle (29). It has also been estimated that the 
majority (96-100%) o f glucose taken up by the muscle is oxidized during exercise (13). 
Jeukendrup et al. (14) has suggested that the complete suppression o f hepatic glucose 
production (glucose Ra), in response to aggressive exogenous glucose ingestion, is a 
function o f elevated insulin concentrations rather than high plasma glucose concentration. 
Despite complete suppression o f hepatic glycogenolysis with large glucose feedings 
(22% solution; —180 g hr’*) during cycling at 50% VOzmax for 120 minutes, Jeukendrup 
et al. (14) did not demonstrate a reduction in the estimated rate of muscle glycogenolysis 
(estimated as the difference between total CHO oxidation and plasma glucose oxidation). 
This is in contrast to our findings in which a high insulin response concomitantly 
occurred with a reduction in muscle glycogenolysis, which was directly measured via 
biopsy. As previously mentioned, hepatic glycogenolysis cannot be determined from our 
study, but the relationship between the glucose, insulin, and muscle glycogen responses 
suggests that low intensity exercise (50% VOzmax) with periodic rest periods results in 
both higher blood glucose and insulin levels and sparing o f muscle glycogen via 
increased exogenous CHO uptake and oxidation. The discrepancy between the current
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study and that o f Jeukendrup et al. (14) is likely a function o f the exercise duration and 
the short rest periods between exercise segments.
Paragraph 40: Despite significantly higher blood glucose concentrations for much o f the 
CHO trial compared to the control trial, Hargreaves et al. (12) found no difference in the 
circulating insulin concentrations and muscle glycogen utilization between PLA vs. CHO 
feedings when subjects were provided with 30 g CHO every 30 minutes, during 90 
minutes o f cycling at 70% VOzmax. Although this feeding schedule (60 g hr'^) is the 
same as the present investigation, it is possible that the higher exercise intensity 
suppressed insulin release and reduced exogenous CHO uptake, thereby limiting 
glycogen sparing. Additionally, the absence o f rest periods in Hargreaves et al.’s study 
possibly increased glycogenolysis or did not promote glycogen resynthesis.
Paragraph 41: Previous research has primarily examined the role o f muscle glycogen 
during exercise of higher intensity when there are likely a high number of muscle fibers 
being recruited and glycogen depletion is more likely (12, 20, 25, 26, 27). The current 
study indicates that glycogen depletion may be a source o f muscle fatigue even at 
moderate intensities during extended, discontinuous work. Support for these findings is 
provided by a study by Febbraio and Dancey (7) who concluded that muscle glycogen 
availability was a limiting factor during prolonged exercise (~ 2.6 to 3.6 hours) 
performed below the lactate threshold. It has been suggested that during intermittent, 
lower-intensity activities CHO supplementation may allow for muscle glycogen 
resynthesis in non-active type II fibers (25, 26) or that reduced muscle glycogenolysis is
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primarily limited to type I fibers (25, 26, 30). Interestingly, the current protocol included 
several higher-intensity intervals during each cycle and treadmill exercise segment, 
resulting in a diverse recruitment o f fiber types. It is possible that the five minutes o f rest 
every 30 minutes and/or the incremental intensities may have contributed to the 
preservation or resynthesis o f glycogen during the CHO trial.
Paragraph 42: If glycogen depletion is a primary contributor to muscle fatigue, then a 
reduced rate o f glycogenolysis could positively affect work output at the end o f any 
physically challenging event. This may be particularly applicable to improving 
performance in ultra-endurance competitions or physically demanding occupations such 
as wildland firefighting and certain military operations. Evidence from our lab also 
suggests that long-duration workers (wildland firefighters) have improved reaction time 
and improved performance in some cognitive tasks when given exogenous CHO 
throughout the work shift when compared to a placebo.
Paragraph 43: Regardless o f how carbohydrate feedings are eliciting their fatigue- 
delaying effects: via decreasing the rate of muscle glycogenolysis, maintaining 
euglycemia, or attenuating the onset of some other fatigue-causing factor, it is apparent 
from this study that exogenous carbohydrate provided at a rate o f 60 g hr‘‘ can 
significantly alter muscle substrate oxidation during prolonged, intermittent activity of 
varied intensity. The maintenance o f total CHO oxidation rates and blood glucose levels 
during both cycle and treadmill exercise (with a slight, although significant drop during 
the final treadmill session) in conjunction with decreased rates o f muscle glycogenolysis
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is an important metabolic finding. These results suggest that exogenous CHO may be 
able to prevent hypoglycemia while also providing enough supplemental substrate to 
maintain whole-body CHO oxidation and reduce glycogenolysis even during exercise 
lasting as long as 8 hours. This study establishes links between the metabolic demands o f 
shorter duration exercise and extended muscle work. Further research remains to be 
conducted to evaluate the effects o f exogenous CHO feedings during ultra-endurance 
activity on glucose kinetics and fiber-specific muscle glycogenolysis. Additionally, 
while we attempted to model the demands on wildland firefighters or working military 
personnel, these data and the majority o f the other data regarding the effectiveness of 
exogenous CHO during longer work bouts have been collected in the laboratory. It is 
suggested that future studies attempt to define the effects o f CHO supplementation on 
muscle function during ultra-endurance work under field conditions.
Paragraph 44: In conclusion, the significant increase in blood glucose concentrations, in 
combination with the decreased rate o f muscle glycogenolysis and the maintenance of 
whole-body CHO oxidation (cycle), suggests that perhaps a feeding strategy which 
provides at least 60 g CHO hr'^ may not only prevent hypoglycemia but also provide 
enough supplemental CHO to sustain total CHO oxidation with less reliance on muscle 
glycogen stores during intermittent, varied-intensity exercise lasting as long as 8 hours.
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C aptions to Figures:
Figure 1. Exercise protocol— intensity breakdown o f 25 minutes on each mode.
Figure 2. Plasma lactate concentration (mmol • L'^). Values are means ± SD. * p<0.05 
average [lactate] CHO vs. average [lactate] PLA; f  p<0.05 post vs. pre.
Figure 3. Plasma glucose concentration (mmol • L'*). Values are means ± SD. * p<0.05 
CHO vs. PLA for the corresponding hour; f  p<0.05 time point vs. pre (within trial).
Figure 4. Plasma insulin concentration (pIU • mL'*). Values are means ± SD. * p<0.05 
CHO vs. PLA for the corresponding hour; f  p<0.05 time point vs. pre (within trial).
Figure 5a. Whole-body CHO oxidation (g • min‘‘) on cycle ergometer. Values are 
means ± SD. * p<0.05 CHO vs. PLA for corresponding hour; f  p<0.05 time point vs. 
hour 1 (within trial).
Figure 5b. Whole-body CHO oxidation (g • min'*) on treadmill. Values are means ±
SD. * p<0.05 vs. PLA for corresponding hour; f  p<0.05 time point vs. hour 1
(within trial).
Figure 6a. Whole-body fat oxidation (g • min'^) on cycle ergometer. Values are means ± 
SD. * p<0.05 vs. PLA for corresponding hour; f  p<0.05 time point vs. hour 1 (within 
trial).
Figure 6b. Whole-body fat oxidation (g • miri*) on treadmill. Values are means ± SD.
* p<0.05 vs. PLA for corresponding hour; f  p<0.05 time point vs. hour 1 (within trial).
Figure 7. Glycogen concentration (mmol • kg wet wt."^). Values are means ± SD. Bars 
indicate where there is a significant difference; p<0.05.
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Males (n — 8)
Age, yr 28.9±  11.5
Height, cm 177.8 ±5 .3
Body mass, kg 74.0 ± 11.6
Body fat, % 9.1 ± 5 .7
Fat-firee mass, kg 66.8 ± 7.6
Cycle ergometer
VOzmax
L-min'^ 4.2 ± 0.6
m lkg‘*-min'* 57.4 ± 7 .6
%VOzmax @ Tvent 66.0 ± 0.1
Treadmill
VOzmax
L*min‘* 4.6 ± 0.5
ml-kg'^-min'^ 62.4 ± 7.4
% VOzmax @ Tvent 62.6 ±0.1
Values are means ± SD. VOzmax = maximal O2 uptake; 
Tvent = ventilatory threshold.
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Table 2. Average prescribed workloads fo r  exercise trials
70%T„.nt 90% T ..nt 100% 110%Tv.n,
Cycle ergometer (watts) 143 ±11 .0  199 ± 11.8 227 ± 15.4 255 ±19.8
Treadmill (percent grade) 9 ± 0 .9  13 ± 1.2 16 ± 1.4 18 ± 1.4
Values are means ± SD. Tvent = ventilatory threshold. Treadmill speed was constant at 
106.8 m ■ m in '\
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T able 3a. Heart rate during cycle ergometer segments
Time (Hours)
1 4 5 8
CHO
70% Tvent 
110% Tvent
132 ± 9  
150 ± 9
133 ± 12 
155 ± 9
138 ± 13 
155 ± 10
142 ± 9  
153 ± 9
PLA
70% Tvent 
110% Tvent
132 ± 10 
151 ± 10
133 ± 12 
152 ± 13
141 ± 12 
157 ± 9
141 ± 10 
154 ± 9
Time x Intensity 
70% Tvent 
110% Tvent
132 ± 10 
151 ±10
133 ± 12 
154±13f
138 ±12* 
156 ± 9 t
141 ±10* 
153± l o t
Values are means ± SD. Units are beats per minute. * p<0.05 vs. hour 1 70% Tvent; t  
p<0.05 vs. hour 1 110% Tvent.
Table 3b. Heart rate during treadmill segments
Time (Hours)
1 4 5 8
CHO
70% Tvent 
110% Tvent
126 ± 12 
153 ± 9
130 ± 9  
154 ± 9
137 ± 14 
155 ± 10
137 ± 16 
151 ± 8
PLA
70% Tvent 
110% Tvent
128 ± 10 
149 ± 11
133 ± 12 
154± 13
139 ± 13 
158 ± 12
135 ± 12 
155 ± 9
Time
138 ± 16 142± 16* 146± 15* 143 ±14*
Values are means ± SD. Units are beats per minute. * p<0.05 vs. hour 1 (main effect for 
time).
82
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
T able 4a. RPE during cycle ergometer segments
Time (Hours)
1 4 5 8
CHO
70% Tvent 
110% Tvent
10.5 ± 0.8 
12.9 ± 0 .8
11.3 ± 0 .9  
13.9 ± 1.1
11.3 ± 0 .9  
14.1 ± 0 .6
13.0 ± 2.3 
15.9 ± 2 .0
PLA
70% Tvent 
110% Tvent
11.0± 1.1 
13.0 ± 0 .9
11.5 ± 0 .9  
14.3 ± 0.9
11.5 ± 0 .9
14.6 ± 1.4
14.8 ± 2.7 
16.0 ±2.3
Time x Intensity 
70% Tvent 
110% Tvent
10.7 ± 0 .9  
12.9 ± 0 .9
11.4 ± 0 .9  
14.1 ± l.Of
11.4 ± 0 .9
14.4 ± L i t
13.8 ±2.0* 
1 5 .9 ± 2 .6 t
Values are means ± SD 
Tvent.
. * p<0.05 vs. hour 1 70% Tvent; f  p<0.05 vs. hour 1 110%
Table 4b. RPE during treadmill segments
Time (Hours)
1 4 5 8
CHO
70% Tvent 
110% Tvent
10.6 ± 0 .7  
13.0 ± 0 .8
11.3 ± 0 .7  
13.9 ± 1.1
11.6± 1.1 
14.0 ± 1.1
12.5 ±2 .8  
15.0 ± 2 .6
PLA
70% Tvent 
110% Tvent
11.3 ±0 .5  
13.5 ± 0 .9
11.1 ± 1.0 
14.3 ± 1.7
11.9 ±0 .8
14.9 ± 1.6
13.7 ± 2 .9  
16.1 ± 2 .8
Time
12.1 ± 1.4 12.5 ± 1.7 12.9 ± 1.6 14.0 ±2.9*
Values are means ± SD. * p<0.05 vs. hour 1 (main effect for time).
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F igure 5b
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Figure 6a
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Figure 6b
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Figure 7
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Wormed Consent Form
Effects of carbohydrate feedings on blood glucose and muscle glycogen during extended exercise
Principal Investigator: Brent C. Ruby, Ph J).
Location: Human Performance Laboratory
McGiU Hall #121 
The University of Montana 
Missoula, MX 59812 
(406) 243-2117/(406) 243-4780
Purpose
The purpose o f this project is to detennine the ejSects o f high carbohydrate food/drink sources on blood 
glucose, and changes in muscle glycogen during extended exercise. The information collected in this study 
will help determine if  the effects o f srqtplemental carbohydrate consunption will alter work performance 
and minimize &tigue during extended exercise/work bouts.
As a particq>ant in this study you will congtlete the following assessments. 1) a pre-screening assessment 
which involves a healdi/exercise history questionnaire (Par-Q), 2) a measure o f percent body fat obtained 
using a underwater weighing, 3) a maximal treadmill test and maximal cycle ergometer test to measure 
aerobic fitness levels, 4) two eight-hour work/rest sessions involving cyclir% and treadmill walking/jogging 
5) the corrq>letion o f a mood state survey (the Profile o f Mood States) at six tunes during the study, 5) 
collection o f expired gases to determine fuel use during the 8-hour work/rest session, 6) consumption o f 
one o f  two different types o f liquid carbohydrate every hour of exercise, 7) venous blood samples collected 
firom an arm vein (pre-exercise, after 4 and 7 hours and immediately post-exercise) for measures o f  blood 
glucose, lactate, and epinephrine, 8) measures of cognitive performance using a corrputer reaction time, 
verbal, and mafii test, 9) saliva sanples collected at various times before, during and after each exercise 
session, 10) a total o f  four muscle biopsies (two muscle biopsies per 8-hr trial: a) early in the morning 
before the exercise session begins, and b) late in the afternoon after the exercise session is conpleted),
Body Fat Measurement — Underwater Weighing:
This test session will require that you do not eat for a minimal of 3 hours prior to the testing. 
Prior to the test, body weight will be recorded in your bathii^ suit. You will then be asked to 
conplete between 3 — 6 underwater weighing procedures. The underwater weight requires 
diat you are submersed in our weighting tank (similar to a hot tub) and that you maximally 
exhale as much air as possible while underwater. The underwater weight will be recorded 
within 2-4 seconds and then you wUl be signaled to surfiice. This procedure wiU be repeated 
until three meastnements have been obtained that are within 100 grams o f each other. A nose 
clip will be provided upon request. This test wül take approximately 30 minutes.
Maximal Exercise Test — Treadmill:
This test will consist o f walking and running on a motorized treadmill to a maximal effort. 
The speed and grade o f  the treadmill will progress to fiitigue. You will be encouraged to 
continue to walk/run until exhaustion. Dtning the entire testing session on the treadmill, you 
will wear a nose clip and headgear toat will support a moutlpiece. This will allow us to 
measure the amount o f oxygen the body uses during the exercise. Heart rate will be measured 
using an elastic chest strap that is worn on the skin under your shirt around your chest. This 
test will take approximately 45 minutes to 1-hour. You will be adced to fitst for 
approximately 3 hours prior to this test.
Maximal Exercise Test -  Cycle:
This test will consist o f riding on a laboratory exercise cycle to maximal effort The 
resistance o f the cycle will increase each minute and wiU progress to fatigue. You will be 
encouraged to continue to ride until exhaustion. During this test you will wear a nose clip and
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headgear that will stqpport a mouthpiece. This will allow us to measure the amount o f  oxygen 
that the body uses during this exercise. Heart rate will be measured using an elastic chest 
strap that is worn on the skin under your shirt around your chest. This test will take 
approximately 45 minutes to 1 hour. You will be asked to fast for approximately three hours 
prior to this test.
8-hour Exercise/Rest Session:
You will be asked to report to die laboratory after a 12 hour fast, at approximately 6:00 AM. 
Upon arrival, you will be asked to void your bladder and your nude body weight will be 
measured. A cognitive ftmction test using a computer program will evaluate your decision­
making skills and reaction times. A saliva sangle will be collected using a cotton swab that is 
placed in your mouth near your cheek for approximately 5 minutes. Prior to exercise, a blood 
sanqiles will be obtained finm an arm vein (7-10 ml). A muscle biopsy will then be obtained 
ftom your front thigh muscle (diis is detailed below). You wUl then be provided with a small, 
standardized breakfast (apple, granola bar, juice box). Each o f dte 8-hr sessions will be 
convicted as eight, 1-hour sessions as follows:
1) Twenty-five minutes of cycling. This exercise period will be initiated widi six minutes 
o f cycling at 40-50% of your maximal capacity followed by a sequence of intervals that 
includes three, two minute cycling intervals coirpleted at approximately 70-75% of your 
maximal capacity. Each o f these intervals will be followed by a 1-minute active recovery 
period, cycling at 40-50% of your maximal capacity. This series o f intervals will then be 
followed by a remaining 10 minutes o f cycling at 40-50% o f your maximal capacity.
2) Five-minute rest and transition to treadmill.
3) Twenty-five minutes of treadmill exercise. This exercise period will be initiated with 
six minutes o f treadmill walking at 40-50% o f your maximal capacity followed by a 
sequence o f intervals that includes three, two minute treadmill jog/run intervals 
completed at approximately 70-75% of your maximal capacity. Each o f these intervals 
will be followed by a 1-minute active recovery period, walking at 40-50% o f your 
maximal capacity. This series o f intervals wUl then be followed by a remaining 10 
minutes o f walking at 40-50% o f your maximal capacity.
4) Five-minute rest.
Additional saliva samples will be collected after each hour of exercise. After the conpletion 
o f die fourth 1-hr session, a second blood sanple wiU be obtained and you wUl be asked to 
conplete the computer cognitive performance test and provide a saliva sample. You will then 
be given a small snack lunch and an additional 20 minutes o f rest. The remaining four 1-hr 
sessions wUl be identical to those above. A third blood sample will be obtained after die 7*" 
hour o f exercise. After the final S"* exercise period, a fourth blood sample and die final sahva 
sanqile will be obtained. This will be followed by a post exercise nude body measurement 
and the post-exercise muscle biopsy. Following the completion of the muscle biopsy, you 
will be provided with a meal in the lab.
M uscle Biopsies:
A total o f four muscle biopsies will be obtained from your front thigh muscle (vastus lateralis, 
approximately 6 inches up from the kneecap on die lateral side o f your thigh). The muscle 
biopsy procedure requires that the site be sterilized. After the site is cleaned, a small amount 
o f lidocaine will be injected just under the skin surfru:e. Additional small amounts o f 
hdocaine will be injected around a small 1-inch area around the site on the leg. After the area 
is treated with the lidocaine (approximately 5 ml, 1% lidocaine), a small incision 
(approximately 1/4 inch long) will be made through the skin and to a dqUb o f approximately 
3/4-1.5 inches. The biopsy needle will then be inserted through the incision and the sample 
obtained. After the sample is obtained, the site will be cleaned and closed with steri-strips
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and/or a single stitch and bandaid and wrapped with an ace bandage. A flexible ice pack will 
then be placed on the site for 10 minutes. The biopsy samples will be obtained a) prior to the 
8-hour exeicise/rest session, and b) immediately after die 8-hour exercise/rest session (on the 
same leg but approximately 2 inches above the initial sanple). This will be repeated for the 
second trial using the opposite leg. The muscle biopsies will be used to evaluate alterations in 
muscle carbohydrate and fat stores in response to physical activity. Latex fiee bandages will 
be provided if  subjects have a known allergy to latex. All o f the muscle biopsies will be 
conducted by Dr. Brent Ruby, the study director.
Body W eight:
Your nude body weight will be measured using a digital scale prior to, after 4-hours, and 
immediately following each 8-hour exercise/rest session. All measures will be done in 
private.
Surveys and Cognitive Testing:
You will be asked to conplete a 60-question survey that has been developed to assess you 
opinions regarding your current mental state prior to, at the mid point and immediately 
following the each 8-hour exercise/rest session. You are asked to provide an accurate and 
trotbfiil response to each question. You will also complete a computer directed test that will 
measure reaction time and accuracy to a series o f questions.
Supplemental C arbohydrate Beverage:
During each 8-hour exercise/rest session, you will be given one o f two different carbohydrate- 
containing beverages. You will be asked to drink a predetermined amount (approximately 
100 ml, approximately 3.4 oz, approximately 1/2 cup) of the solution at the top o f each hour 
and 30 minutes into each o f  the eight-Ihr exercise periods. You will also be provided with a 
smalL standardized lunch at the 4-hour midpoint.
A rm  vein blood samples :
During each 8-hour exercise session, periodic blood satrples will be collected (pre-exercise, 4 
hour, 7 hour, post-exercise). These sanqjles are being collected to evaluate changes in blood 
sugar throughout each exercise session as well as lactate and epinephrine. All o f  the blood 
sarrples will be obtained by Dr. Brent Ruby, the study director and trained phlebotomist.
Risks and Discomfort
1. Mild discomfbit may result during and after the exercise. These discomforts include shortness of 
breath, tired or sore legs, nausea and possibility o f vomiting,
2. Muscle soreness after the tests may occur as a result o f the exercise, but should not persist.
3. Certain changes in body function take place when any person exercises. Some o f these changes are 
normal and others are abnormal. Abnormal changes may occur in blood pressures, heart rate, heart 
dhythm or extreme shortness o f bread*. Very rare instances of heart attack have occurred. Every effort 
will be made to mininhze possible problems by the preliminary evaluation and constant surveillance 
during testing. A trained CPR technician will be on hand at all times and the laboratory has standard 
emergency procedures should any potential problems arise.
4. You will be informed o f any new fmdii%s diat may affect your decision to remain in the study.
5. The muscle biopsy and blood sampling techniques may cause some local and tenqiorary discomfort. It 
is normal to have the sensation o f a deep tissue bruise around the site o f the muscle biopsy. This pain 
should be manageable and not above the pain associated ffom a “charhe horse” type bruise.
6. There is a minor risk o f  infection associated with blood sarr^ling and the muscle biopsy. Should you 
notice unusual redness, swelling or drainage at the biopsy incision site or at the sites of the blood 
san^ling sites you should seek medical attention and then notify Brent Ruby, study director.
7. There are minimal risks associated widi the use o f lidocaine (the local anesthetic). The risk o f a 
reaction to the lidocaine is extremely low (approximately 1/1,000,000). However to minimize this 
risk, no more than 5-9 ml o f a 1% lidocaine solution will be used per biopsy.
8. During any o f  the exercise tests should synqrtoms, such as chest discomfort, unusual shortness o f 
breath or other abnormal findings develop, die exercise physiologist conducting the research will
Revised 11/2004
96
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
temdnate the test. Guidelines by the American College of Sports Medicine will be followed to 
determine when a test should be stopped. These synqitoms include moderate to severe angina (chest 
pain), increased dizziness, shortness o f breath, fatigue and your desire to stop.
9. You will be excluded from participation if  you have a known history o f allergic reactions to local 
anesthetics.
Benefits of Participating in This Study
1. Upon completion o f the preliminary tests (body fat, treadmill, cycle and arm ergometer max tests), you 
wUl be paid $25. Upon conpletion o f the first 8-hour exercise/rest session, you will be paid another 
$75. Upon completion o f  the second 8-hour session, you will be paid another $100. Therefore, upon 
completion o f the entire study, you will be paid a  total o f $200. If  you decide to wididraw at any time, 
you will be compensated f<m the test sessions you have completed or initiated.
2. The information from these tests will provide you with an accurate assessment o f you aerobic fitness 
and body composition that can be compared with norms for your age and sport but may be o f  little 
benefit to your understanding o f  your personal fitness. There are no other direct benefits to the 
participants in the study.
3. There is no promise that you will receive any benefit outside o f the financial payment as a result o f 
talfing part in this study.
Confidentiality
All results will be kept in strict confidence among the subject involved and fire Principal Investigators and 
odret Co-Investigators. During the entire period o f data collection, subject records will be kept within the 
Human Performance Laboratory and will be locked under the direction o f the Principal Investigator.
Compensation for Injury
Although we believe that the risk o f taking part in this study is minimal, the following liability statement is 
required in all University o f Montana consent forms. In the event that you are injured as a result o f  this 
research you should individually seek appropriate medical treatment. I f  the injury is caused by negligence 
o f  the University or any o f its employees, you may be entitled to reimbursement pursuant to the 
Comprehensive State Insurance Plan established by the Department o f Administration under the authority 
o f  M.C.A., T itlel, Chapter 9. In the event o f  a claim fo r  such injury, further information may be obtained 
from  the University’s Claim representative or University Legal Counsel.
Voluntary Participation and Withdrawl
It is important that you realize that you are fi-ee to withdraw fiom the study at any time. As mentioned 
above, even if  you decide to drop out of the study, you will receive full compensation for all the test 
sessions you complete or initiate.
A copy o f this consent form will be provided for you at your request. In addition, the data collected during 
this study will be done at no cost to you.
Statement o f Consent
I have read the above statements and understand the risks involved with this study. I authorize Brent C. 
Ruby and such assistants that he may designate, to administer and conduct the testing as safely as possible 
with a minimal amount of discomfort. I f  I have additional questions, I may contact Brent C. Ruby at home 
(406) 542-2513, cell (406) 546-4691 or at the Human Performance Laboratory (406) 243-2117.
Participant (print)
Signature Date
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Permanent Mailing Address 
(for payment purposes)
Investigator/Witness Signature ____________________________________________
(print)
Investigator/Witness Signature ____________________________________________  Date
Subject statement of consent to be photographed during data collection
During the study, I understand that pictures may be taken. I provide my consent to having my picture taken 
during the course o f  the research study. 1 provide my consent that my picture may be used in some 
presentations related to this study. I f  pictures are used at any time for presentation, names will not be 
associated with them.
Signature   Date ________
Approval Expires On 
Date Approved by UM 11%  _ H
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(Hour 1̂
6:15 AM subject arrives (Hour 2) 9:00 AM begin exercise (cycle) (Hour 4) 11:00 AM begin exerc
6:30 AM *HRV "drink provided "drink provi
6:45 AM "blood draw 9:15 AM drink provided 11:15 AM drink provic
"biopsy 9:25 AM stop exercise 11:18AM begin gas c
"saliva "begin 6 min rest 11:25 AM stop exerci:
7:15 AM subject eats breakfast 9:30 AM begin exercise (treadmill) "begin 5 mi
7:55 AM void bladder (toilet) "drink provided 11:30 AM begin exerc
"body weight 9:45 AM drink provided "drink provi
"start HR monitor 9:55 AM stop exercise 11:45 AM drink provic
7:59 AM jump test "jump test
"remainder of 5 min rest
11:48 AM begin gasc 
11:55 AM stop exerci: 
"jump test 
"blood drav 
"saliva
8:00 AM BEGIN EXERCISE (cycle) fHour 3̂ 10:00 AM begin exercise (cycle) "lunch
"start main clock "drink provided
"drink provided 10:15 AM drink provided
8:15 AM drink provided / calibrate 10:25 AM stop exercise
8:18 AM begin gas collection "begin 5 min rest
8:25 AM stop exercise 10:30 AM begin exercise (treadmill)
"begin 5 min rest "drink provided
8:30 AM begin exercise (treadmill) 10:45 AM drink provided
"drink provided 10:55 AM stop exercise
8:45 AM drink provided "jump test
8:48 AM begin gas collection "remainder of 5 min rest
8:55 AM stop exercise
"jump test
"remainder of 5 min rest
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fHourS^ 12:30 PM BEGIN EXERCISE (cycle)
‘restart main clock 
•drink provided 
drink provided I  calibrate 
begin gas collection 
stop exercise 
•begin 5 min rest 
1:00 PM begin exercise (treadmill) 
•drink provided 
drink provided 
begin gas collection 
stop exercise 
•jump test 
•begin 5 min rest
12:45 PM 
12:48 PM 
12:55 PM
1:15 PM 
1:18 PM 
1:25 PM
(Hour 6) 1:30 PM begin exercise (cycle)
•drink provided 
1:45 PM drink provided 
1:55 PM stop exercise
•begin 5 min rest 
2:00 PM begin exercise (treadmill) 
•drink provided 
2:15 PM drink provided 
2:25 PM stop exercise 
•jump test 
•blood draw
•remainder of 5 min rest
(Hour 7) 2:30 PM begin exercise (cycle)
•drink provided 
2:45 PM drink provided 
2:55 PM stop exercise
•begin 5 min rest 
3:00 PM begin exercise (treadmill) 
•drink provided 
3:15 PM drink provided 
3:25 PM stop exercise 
•jump test
•remainder of 5 min rest
(Hour 81 3:30 PM begin exercise (cycle)
•drink provided 
3:45 PM drink provided I  calibrate 
3:48 PM begin gas collection 
3:55 PM stop exercise
•begin 5 min rest 
4:00 PM begin exercise (treadmill) 
•drink provided 
•call I  order food 
4:15 PM drink provided 
4:18 PM begin gas collection 
4:25 PM stop exercise 
•jump test 
•blood draw 
•biopsy 
•saliva 
•HRV
•collect final urine in bucket 
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8 HOUR STUDY -  Jamie Wagner
Baseline Testing Baseline Testing Baseline Testing Baseline Testing
Subject # Age
Height
(cm)
Weight
(kg)
% Body 
Fat
Lean Body 
Mass (kg)
Cyc
V02max
(ml/kg/min)
Cyc
V02max
(L/min)
1 48 175.3 84.3 17.8 69.3 42.96 3.57
2 19 177.8 62.4 3.1 60.5 67.63 4.22
3 21 182.9 79.5 4.8 75.7 58.39 4.64
4 23 175.3 67.3 4.5 64.3 54.63 3.68
5 28 182.9 89.4 14.0 76.9 55.64 4.97
7 25 177.8 64.7 9.0 58.9 55.31 3.72
8 46 182.9 84.0 14.7 71.6 58.67 4.92
9 21 167.6 60.0 4.5 57.3 65.80 3.95
Average 28.9 177.8 74.0 9.1 66.8 57.38 4.21
STD 11.53 5.27 11.56 5.71 7.64 7.57 0.57
Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Subject # Trial
HR 1st Int 
Cyc 1
HR 2nd Int 
Cyc 1
HR 3rd Int 
Cyc 1
HR 
Last 5 Min 
Cyc 1
HR 1st Int
Cyc 2
HR 2nd Int 
Cyc 2
1 A 145 145 144 133 153 148
2 A 153 149 148 137 154 158
3 A 153 151 144 128 148 145
4 A 161 157 157 134 148 155
5 A 153 153 147 134 157 149
7 A 148 146 144 134 155 149
8 A 131 129 125 112 138 134
9 A 159 160 162 143 166 168
Average A 150.38 148.75 146.38 131.88 152.38 150.75
STD A 9.40 9.48 10.91 9.06 8.12 9.97
SE A 3.32 3.35 3.86 3.20 2.87 3.52
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
Subject # Trial
HR 1st Int
Cyc 1
HR 2nd Int
Cyc 1
HR 3rd Int 
Cycl
HR 
Last 5 Min 
Cyc 1
HR 1st Int 
Cyc 2
HR 2nd Int 
Cyc 2
1 6 136 142 132 125 138 137
2 B 157 157 151 143 164 160
3 B 147 142 137 129 150 144
4 B 156 155 147 133 153 160
5 B 163 159 153 142 165 156
7 B 147 147 145 129 147 150
8 B 140 137 135 114 131 128
1 9 B 160 161 155 140 158 155
Average B 150.75 150.00 144.38 131.88 150.75 148.75
STD B 9.74 9.12 8.73 9.83 11.97 11.57
SE B 3.44 3.22 3.09 3.48 4.23 4.09
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Baseline Testing Baseline Testing Baseline Testing Baseline Te:
Cyc 70% 
VT 
(ml/kg/min)
Cyc 
Watts 
70% VT
Cyc 90% 
VT 
(ml/kg/min)
Cyc 
Watts 
90% VT
Cyc 100% 
VT 
(ml/kg/min)
Cyc 
Watts 100% 
VT
Cyc 110% 
VT 
(ml/kg/min)
23.14 157 29.75 202 33.06 225 36.37
30.78 160 39.57 203 43.97 225 48.37
23.66 140 30.42 194 33.80 221 37.18
26.43 132 33.98 187 37.75 215 41.53
22.79 150 29.3 212 32.56 243 35.82
25.57 135 32.88 189 36.53 216 40.18
28.76 139 36.98 218 41.09 258 45.20
29.52 133 37.95 187 42.17 215 46.39
26.33 143 33.85 199 37.62 227 41.38
3.08 10.98 3.96 11.76 4.40 15.44 4.84
Trial A Trial A Trial A Trial A Trial A Trial A Trial A
HR 3rd Int 
Cyc2
HR 
Last 5 Min 
Cyc 2
HR 1st Int 
Cyc 3
HR 2nd Int 
Cyc 3
HR 3rd Int 
Cyc 3
HR 
Last 5 Min 
Cyc 3
HR 1st Int 
Cyc4
144 132 155 152 147 136 157
151 142 158 157 158 146 159
136 XXXXX XXXXX XXXXX XXXXX XXXXX XXXXX
141 125 148 145 139 121 153
145 134 155 153 148 133 157
145 135 150 155 151 137 160
127 111 137 131 126 108 136
162 147 163 165 163 144 165
143.88 132.29 152.29 151.14 147.43 132.14 155.29
10.26 11.74 8.36 10.71 12.23 13.41 9.25
3.63 4.15 2.96 3.79 4.32 4.74 3.27
Trial B Trial B Trial B Trial B Trial B Trial B Trial B
HR 3rd Int
Cyc 2
HR 
Last 5 Min 
Cyc 2
HR 1st Int
Cyc 3
HR 2nd Int
Cyc 3
HR 3rd Int
Cyc 3
HR 
Last 5 Min 
Cyc 3
HR 1st Int
Cyc 4
139 120 144 141 131 119 146
157 148 159 158 156 144 161
141 122 144 140 138 125 150
144 128 148 149 146 126 147
151 134 164 159 154 140 172
137 128 149 139 139 126 151
110 122 124 131 130 112 129
137 135 154 146 138 137 163
139.50 129.63 148.25 145.38 141.50 128.63 152.38
13.86 9.26 12.08 9.66 9.71 10.90 13.07
4.90 3.27 4.27 3.42 3.43 3.85 4.62
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sting Baseline Testing Baseline Testing
Cyc 
Watts 
110% VT
TM
V02max
(ml/kg/min)
TM
V02max
(Umin)
TM 70% 
VT 
(ml/kg/min)
TM% 
grade 70% 
VT
TM90%
VT
(ml/kg/min)
TM% 
grade 90% 
VT
247 52.27 4.41 23.93 7 30.76 11
248 70.44 4.40 29.93 10 38.48 15
248 66.02 5.25 28.19 9 36.24 13
243 62.65 4.21 27.17 8 34.93 13
274 59.18 5.29 24.96 9 32.09 13
243 56.98 3.69 26.39 9 33.93 13
297 57.62 4.84 28.63 9 36.81 14
242 74.03 4.44 27.98 9 35.97 14
255 62.40 4.57 27.15 9 34.90 13
19.80 7.35 0.54 1.98 0.89 2.55 1.16
Trial A Trial A Trial A Trial A Trial A Trial A Trial A
HR 2nd int 
Cyc 4
HR 3rd Int 
Cyc 4
HR 
Last 5 Min 
Cyc 4
HR 1st Int 
Cyc 5
HR 2nd Int 
Cyc 5
HR 3rd Int 
Cyc 5
HR 
Last 5 Min 
Cyc 5
157 151 136 158 156 154 139
166 162 151 163 166 164 154
XXXXX XXXXX 134 XXXXX XXXXX XXXXX 146
155 150 123 151 146 136 119
149 155 131 156 161 152 142
154 150 139 159 156 153 144
133 126 111 135 132 132 118
166 159 140 165 165 157 141
154.29 150.43 133.13 155.29 154.57 149.71 137.88
11.28 11.73 11.99 10.05 12.03 11.50 12.78
3.99 4.15 4.24 3.55 4.25 4.07 4.52
Trial B Trial B Trial B Trial B Trial B Trial B Trial B
HR 2nd Int 
Cyc 4
HR 3rd Int 
Cyc 4
HR 
Last 5 Min 
Cyc 4
HR 1 st Int
Cyc 5
HR 2nd Int
Cyc 5
HR 3rd Int
Cyc 5
HR 
Last 5 Min 
Cyc 5
145 145 128 150 153 148 137
159 164 150 162 167 167 156
151 151 133 162 162 159 143
149 141 127 150 154 146 131
162 160 142 174 171 164 155
145 144 133 157 154 143 143
139 137 112 145 138 129 118
162 157 142 152 152 147 141
151.50 149.88 133.38 156.50 156.38 150.38 140.50
8.65 9.69 11.66 9.29 10.27 12.44 12.38
3.06 3.42 4.12 3.28 3.63 4.40 4.38
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Baseline Testing
TM 100% VT 
(ml/kg/min)
TM % grade 
100% VT
TM 110% VT 
(ml/kg/min)
TM % grade 
110% VT
34.18 13 37.60 15
42.75 18 47.03 20
40.27 16 44.30 18
38.81 16 42.69 18
35.66 15 39.23 18
37.70 15 41.47 17
40.90 16 44.99 18
39.97 16 43.97 18
38.8 16 42.7 18
2.83 1.41 3.11 1.39
1 Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
HR 1st Int 
Cyc 6
HR 2nd Int 
Cyc 6
HR 3rd Int 
Cyc 6
HR 
Last 5 Min 
Cyc 6
HR 1st Int 
Cyc 7
HR 2nd Int 
Cyc 7
HR 3rd Int 
Cyc 7
HR 
Last 5 Min 
Cyc 7
164 166 158 140 160 157 151 140
164 167 163 149 164 158 152 143
XXXXX XXXXX XXXXK XXXXX XXXXX XXXXX XXXXX XXXXX
150 149 145 125 149 156 155 128
162 155 151 145 164 165 155 146
158 156 156 141 158 152 151 142
138 135 130 113 136 134 128 112
159 160 153 141 158 157 152 142
156.43 155.43 150.86 136.29 155.57 154.14 149.14 136.14
9.45 11.00 10.79 12.68 10.00 9.69 9.48 12.09
3.34 3.89 3.82 4.48 3.53 3.42 3.35 4.27
1 Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
HR 1st Int 
Cyc 6
HR 2nd Int 
Cyc 6
HR 3rd Int 
Cyc 6
HR 
Last 5 Min 
Cyc 6
HR 1st Int 
Cyc 7
HR 2nd Int 
Cyc 7
HR 3rd Int 
Cyc 7
HR 
Last 5 Min 
Cyc 7
153 154 152 135 152 156 149 135
167 170 165 157 164 157 154 153
158 158 153 138 156 158 161 146
150 150 142 126 150 150 147 129
175 171 166 153 171 171 162 147
155 152 149 140 153 153 152 137
139 135 123 117 139 130 132 114
150 15Ï 142 139 157 152 149 133
155.88 155.13 149.00 138.13 155.25 153.38 150.75 136.75
11.06 11.59 13.86 13.01 9.53 11.41 9.38 12.24
3.91 4.10 4.90 4.60 3.37 4.04 3.32 4.33
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1 Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min
Cyc 8 Cyc 8 Cyc 8 Cyc 8 TM 1 TM 1 TM 1 TM 1
152 159 155 147 144 140 133 119
150 136 136 134 156 154 145 126
XXXXX XXXXX XXXXX 155 163 157 152 137
156 157 152 129 152 148 146 106
166 160 159 151 158 154 147 134
153 152 148 142 158 156 152 139
136 136 131 139 135 130 125 113
158 157 150 141 156 157 156 134
153.00 151.00 147.29 142.25 152.75 149.50 144.50 126.00
9.15 10.55 10.16 8.60 9.05 9.77 10.46 12.17
3.23 3.73 3.59 3.04 3.20 3.45 3.70 4.30
1 Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min
Cyc 8 Cyc 8 Cyc 8 Cyc 8 TM 1 TM 1 TM 1 TM 1
156 159 158 146 141 135 128 117
159 146 143 158 157 157 152 133
156 155 154 132 160 157 149 131
148 145 146 130 151 152 146 130
170 165 163 150 166 165 164 146
144 153 151 143 144 148 142 128
141 139 135 129 133 126 122 114
156 155 155 136 140 133 130 125
153.75 152.13 150.63 140.50 149.00 146.63 141.63 128.00
9.24 8.37 8.96 10.47 11.36 13.78 14.08 9.91
3.27 2.96 3.17 3.70 4.02 4.87 4.98 3.51
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1 Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min
TM2 TM2 TM 2 TM2 TM3 TM3 TM3 TM 3
148 143 136 121 152 147 140 121
158 158 147 131 156 159 155 136
XX X X X XXXXX XX XX X XXXXX XXXXX XXXXX XXXXX XXXXX
127 125 148 132 148 142 141 125
157 151 144 130 158 153 147 130
159 155 151 139 159 158 155 139
134 133 126 110 133 131 123 111
158 159 152 132 158 157 155 136
148.71 146.29 143.43 127.86 152.00 149.57 145.14 128.29
13.14 13.15 9.34 9.48 9.26 10.29 11.75 10.00
4.64 4.65 3.30 3.35 3.27 3.64 4.16 3.53
1 Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min
TM2 TM2 TM2 TM2 TM3 TM3 TM3 TM3
135 133 126 111 138 132 128 114
156 154 154 132 161 160 156 138
159 153 148 128 160 151 149 135
148 147 142 126 146 146 140 124
163 161 157 144 169 164 162 145
146 143 137 123 143 142 140 126
138 132 128 116 139 137 127 115
142 136 132 122 146 148 142 129
148.38 144.88 140.50 125.25 150.25 147.50 143.00 128.25
10.13 10.71 11.74 10.07 11.51 10.85 12.34 10.85
3.58 3.79 4.15 3.56 4.07 3.84 4.36 3.83
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! Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
HR 1st Int 
TM4
HR 2nd Int 
TM4
HR 3rd Int 
TM4
HR 
l_ast 5 Min 
TM4
HR 1st Int 
TM5
HR 2nd Int 
TM 5
HR 3rd Int
TM5
HR 
Last 5 Min 
TM5
154 148 141 124 155 155 149 128
161 161 155 139 162 164 162 143
XXXXX XXXXX XXXXX XXXXX XXXXX XXXXX XXXXX 158
152 157 129 124 154 156 151 124
159 153 151 131 159 153 151 139
162 159 154 142 161 161 158 150
135 131 125 115 134 133 128 115
158 156 151 134 157 158 157 136
154.43 152.14 143.71 129.86 154.57 154.29 150.86 136.63
9.29 10.24 12.34 9.48 9.54 10.09 11.10 14.06
3.28 3.62 4.36 3.35 3.37 3.57 3.92 4.97
1 Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
HR 1st Int 
TM4
HR 2nd Int 
TM4
HR 3rd Int 
TM4
HR 
Last 5 Min 
TM4
HR 1st Int 
TM5
HR 2nd Int 
TM5
HR 3rd Int 
TM5
HR 
Last 5 Min 
TM5
138 138 132 119 145 141 139 126
163 166 160 147 165 167 161 154
165 161 152 139 167 166 161 144
146 149 144 130 150 149 142 130
175 170 165 150 180 176 171 158
153 150 146 137 158 145 150 143
140 134 128 118 144 142 136 123
149 136 146 122 156 158 135 135
153.63 150.50 146.63 132.75 158.13 155.50 149.38 139.13
13.00 14.00 12.61 12.46 12.23 13.17 13.55 12.81
4.60 4.95 4.46 4.41 4.32 4.66 4.79 4.53
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1 Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min
TM6 TM6 TM6 TM6 TM 7 TM7 TM7 TM7
155 151 146 127 148 142 139 128
157 161 159 141 160 161 162 146
XXXXX XXXXX XXXXX XXXXX XXXXX XXXXX XXXXX XXXXX
149 144 127 127 161 156 148 126
160 157 153 140 162 157 151 140
160 158 158 151 151 158 154 150
137 131 125 112 133 130 125 110
153 152 149 132 153 153 153 133
153.00 150.57 145.29 132.86 152.57 151.00 147.43 133.29
8.06 10.28 13.96 12.59 10.18 11.08 12.07 13.60
2.85 3.63 4.94 4.45 3.60 3.92 4.27 4.81
1 Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min HR 1st Int HR 2nd Int HR 3rd Int
HR 
Last 5 Min
TM6 TM6 TM6 TM6 TM7 TM7 TM7 TM7
145 142 137 123 148 144 140 127
165 159 162 151 159 157 156 128
165 158 162 151 168 166 162 152
144 145 140 125 142 145 140 123
174 172 168 153 174 169 163 151
155 152 146 140 155 152 150 143
135 134 128 118 136 129 128 114
158 150 140 133 158 155 149 133
155.13 151.50 147.88 136.75 155.00 152.13 148.50 133.88
13.04 11.71 14.37 14.01 12.73 12.88 12.05 13.63
4.61 4.14 5.08 4.95 4.50 4.55 4.26 4.82
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1 Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
HR 1st Int 
TM 8
HR 2nd Int 
TM8
HR 3rd Int 
TM8
HR 
Last 5 Min 
TM8
RPE 
1st Int 
Cyc 1
RPE 
2nd Int 
Cycl
RPE 
3rd Int
Cyc 1
RPE 
Last 5 Min 
Cyc 1
149 148 142 136 13 12 11 10
149 144 138 123 13 13 12 11
XXXXX XXXXX XXXXX 166 13 12 12 9
157 157 144 132 14 14 14 11
163 162 160 140 13 14 14 11
153 154 151 148 11 12 13 11
137 134 128 114 13 12 11 10
152 151 146 134 13 13 13 11
151.43 150.00 144.14 136.63 12.88 12.75 12.50 10.50
8.04 9.18 10.04 15.72 0.83 0.89 1.20 0.76
2.84 3.25 3.55 5.56 0.30 0.31 0.42 0.27
1 Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
HR 1st Int 
TM8
HR 2nd Int 
TM8
HR 3rd Int 
TM8
HR 
Last 5 Min 
TM8
RPE 
1st Int 
Cyc 1
RPE 
2nd Int 
Cyc 1
RPE 
3rd Int 
Cyc 1
RPE 
Last 5 Min 
Cyc 1
147 145 143 132 12 12 12 12
159 163 159 144 13 12 12 12
164 163 139 XXXXX 12 12 11 11
145 143 141 127 14 14 13 11
165 161 160 155 14 15 13 12
151 150 148 127 12 12 11 10
142 135 137 121 13 12 12 9
164 163 164 141 14 14 12 11
154.63 152.88 148.88 135.29 13.00 12.88 12.00 11.00
9.46 11.09 10.63 11.90 0.93 1.25 0.76 1.07
3.34 3.92 3.76 4.21 0.33 0.44 0.27 0.38
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
RPE RPE RPE RPE Last RPE RPE RPE RPE
1st int 2nd Int 3rd int 5 Min Cyc 1st int 2nd Int 3rd Int Last 5 Min
Cyc 4 Cyc 4 Cyc 4 4 Cyc 5 Cyc 5 Cyc 5 Cyc 5
13 12 11 12 14 12 11 10
16 15 14 13 15 14 14 13
14 13 13 11 14 13 12 11
15 15 13 11 14 14 13 11
13 13 13 11 15 14 13 12
13 13 12 11 14 13 13 11
14 13 12 10 14 13 12 11
13 12 11 11 13 13 12 11
13.88 13.25 12.38 11.25 14.13 13.25 12.50 11.25
1.13 1.16 1.06 0.89 0.64 0.71 0.93 0.89
0.40 0.41 0.38 0.31 0.23 0.25 0.33 0.31
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
RPE RPE RPE RPE Last RPE RPE RPE RPE
1st Int 2nd Int 3rd Int 5 Min Cyc 1st int 2nd Int 3rd Int Last 5 Min
Cyc 4 Cyc 4 Cyc 4 4 Cyc 5 Cyc 5 Cyc 5 Cyc 5
14 14 14 12 13 14 13 12
15 15 14 13 16 15 14 13
15 14 14 12 17 16 14 12
15 15 14 11 15 15 12 11
14 14 13 12 14 15 16 12
13 12 12 11 14 13 12 11
15 14 13 10 15 13 11 10
13 12 12 11 13 12 11 11
14.25 13.75 13.25 11.50 14.63 14.13 12.88 11.50
0.89 1.16 0.89 0.93 1.41 1.36 1.73 0.93
0.31 0.41 0.31 0.33 0.50 0.48 0.61 0.33
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
RPE RPE RPE RPE RPE RPE RPE RPE
1st Int 2nd Int 3rd Int Last 5 Min 1st Int 2nd Int 3rd Int Last 5 Min
Cyc 8 Cyc 8 Cyc 8 Cyc 8 TM 1 TM 1 TM 1 TM 1
15 14 13 12 12 11 10 9
19 18 18 18 13 13 12 11
17 16 16 13 13 13 12 10
18 18 17 14 14 15 14 11
16 16 15 12 14 13 14 11
14 14 14 13 13 12 12 11
14 13 12 11 13 12 12 11
14 12 12 11 12 12 12 11
15.88 15.13 14.63 13.00 13.00 12.63 12.25 10.63
1.96 2.23 2.26 2.27 0.76 1.19 1.28 0.74
0.69 0.79 0.80 0.80 0.27 0.42 0.45 0.26
Trial B Trials Trial 8 Trial B Trial B Trial B Trial B Trial B
RPE RPE RPE RPE RPE RPE RPE RPE
1st Int 2nd Int 3rd Int Last 5 Min 1st Int 2nd Int 3rd Int Last 5 Min
Cyc 8 Cyc 8 Cyc 8 Cyc 8 TM 1 TM 1 TM 1 TM 1
17 15 14 14 13 13 13 12
19 18 18 17 13 13 12 12
17 16 15 18 13 13 13 11
17 18 19 15 15 14 13 11
18 18 19 18 15 15 15 11
14 13 13 12 13 12 12 11
13 13 12 12 13 14 13 11
13 13 13 12 13 13 13 11
16.00 15.50 15.38 14.75 13.50 13.38 13.00 11.25
2.33 2.33 2.88 2.66 0.93 0.92 0.93 0.46
0.82 0.82 1.02 0.94 0.33 0.32 0.33 0.16
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
RPE RPE RPE RPE RPE RPE RPE RPE
1st Int 2nd Int 3rd Int Last 5 Min 1st Int 2nd Int 3rd Int Last 5 Min
TM4 TM4 TM4 TM4 TM5 TM5 TM5 TM5
13 12 11 10 13 13 12 11
15 14 13 12 15 15 14 13
14 14 12 11 15 14 14 12
15 14 13 11 14 14 13 11
15 13 13 12 15 15 14 12
13 12 12 12 14 14 13 13
14 13 12 11 14 13 12 11
12 12 12 11 12 12 11 10
13.88 13.00 12.25 11.25 14.00 13.75 12.88 11.63
1.13 0.93 0.71 0.71 1.07 1.04 1.13 1.06
0.40 0.33 0.25 0.25 0.38 0.37 0.40 0.38
Trial B Trials Trials Trial S Trials Trials Trials Trials
RPE RPE RPE RPE RPE RPE RPE RPE
1st Int 2nd Int 3rd Int Last 5 Min 1st Int 2nd Int 3rd Int Last 5 Min
TM4 TM4 TM4 TM4 TM5 TM5 TM 5 TM5
14 14 14 12 14 12 14 12
15 13 13 11 15 14 14 13
16 15 15 13 17 15 14 13
16 15 14 11 16 15 14 11
15 15 14 11 16 17 14 12
13 12 12 11 14 13 13 12
14 13 12 10 15 13 12 11
11 11 11 10 12 11 11 11
14.25 13.50 13.13 11.13 14.88 13.75 13.25 11.88
1.67 1.51 1.36 0.99 1.55 1.91 1.16 0.83
0.59 0.53 0.48 0.35 0.55 0.67 0.41 0.30
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
RPE RPE RPE RPE V02 V02 V02 V02
1st Int 2nd Int 3rd Int Last 5 Min (L/min) (L/min) (L/min) (L/min)
TM8 TM8 TM8 TM8 Cyc 1 Cyc 4 Cyc 5 Cyc 8
12 12 12 11 2.366089 2.306114 2.08737 2.507431
18 18 17 17 2.358239 2.383088 2.345097 1.741045
18 18 18 16 2.176827 2.291836 2.267717 2.377555
17 16 15 11 2.070538 2.048493 2.047048 2.177187
15 14 13 11 2.377406 2.317701 2.439941 2.764799
15 14 14 14 2.012825 2.013397 2.039834 2.197619
14 13 12 11 2.314262 XXXXXX 2.310996 3.14731
11 11 11 9 2.072051 2.000757 1.976194 2.010339
15.00 14.50 14.00 12.50 2.22 2.19 2.19 2.37
2.62 2.62 2.51 2.83 0.15 0.17 0.17 0.44
0.93 0.93 0.89 1.00 0.05 0.06 0.06 0.16
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
RPE RPE RPE RPE V02 V02 V02 V02
1st Int 2nd Int 3rd Int Last 5 Min (L/min) (L/min) (L/min) (L/min)
TM8 TM8 TM 8 TM 8 Cyc 1 Cyc 4 Cyc 5 Cyc 8
15 14 13 12 2.339209 2.281713 2.320451 2.507786
17 17 17 16 2.370697 2.385082 2.422456 2.526468
19 18 XXXXXX XXXXXX 2.203896 2.342254 2.320783 2.090583
18 17 17 14 1.943444 1.935095 1.986034 2.076291
20 20 20 19 2.318248 2.311284 2.396642 2.542278
14 14 14 13 2.06649 2.083497 2.093039 2.179132
14 13 12 11 2.333066 2.266795 2.307571 2.775375
12 12 12 11 2.179523 2.226378 2.156403 2.301827
16.13 15.63 15.00 13.71 2.22 2.23 2.25 2.37
2.80 2.77 3.06 2.93 0.15 0.15 0.15 0.25
0.99 0.98 1.08 1.04 0.05 0.05 0.05 0.09
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
VC02 
(L/min) 
Cyc 1
VC02 
(L/min) 
Cyc 4
VC02 
(L/min) 
Cyc 5
VC02 
(L/min) 
Cyc 8
RER 
Cyc 1
RER 
Cyc 4
RER 
Cyc 5
RER Cyc 
8
2.139098 2.081945 1.871652 2.277737 0.904065 0.902794 0.896656 0.908395
2.072017 2.102749 2.091136 1.515717 0.878629 0.882363 0.891706 0.870579
2.036427 2.063226 2.059365 2.051193 0.935502 0.90025 0.908123 0.862732
1.800479 1.816600 1.868298 1.851422 0869571 0.886798 0.912679 0.850373
2.108129 2.105845 2.230489 2.41013 0.886735 0.908592 0.914157 0.871720
1.802998 1.801439 1.881481 1.856801 0.895755 0.894726 0.922370 0.844915
2.047781 XXXXXX 2.132408 2.995428 0.884853 XXXXXX 0.922722 0.951742
1.849544 1.815811 1.859802 1.881569 0.892615 0.907562 0.941103 0.935946
1.98 1.97 2.00 2.10 0.89 0.90 0.91 0.89
0.14 0.15 0.15 0.45 0.02 0.01 0.02 0.04
0.05 0.05 0.05 0.16 0.01 0.00 0.01 0.01
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
VC02 
(L/min) 
Cyc 1
VC02 
(L/min) 
Cyc 4
VC02 
(L/min) 
Cyc 5
VC02 
(L/min) 
Cyc 8
RER 
Cyc 1
RER 
Cyc 4
RER 
Cyc 5
RER Cyc 
8
2.064453 1.935624 1.947975 1.963704 0882543 0.848321 0.839481 0.783043
2.144013 2.07206 2.088334 2.142725 0.904381 0.868758 0.862073 0.848111
2.039167 2.02104 2.048104 1.665586 0.925256 0.862861 0.882506 0.796709
1.817353 1.688889 1.771106 1.719498 0.935120 0.872768 0.89178 0.828158
2 056969 2.001379 2.119042 2.08335 0.887295 0.865917 0.884171 0.819482
1.815502 1.742928 1.825822 1.72457 0.878544 0.83654 0.872331 0.791402
2.003592 1.876972 2.01372 2.327589 0.858781 0.828029 0.872658 0.838657
1.949259 1.937585 1.911119 1.916837 0.894351 0.870286 0.886253 0.832746
1.99 1.91 1.97 1.94 0.90 0.86 0.87 0.82
0.12 0.13 0.12 0.23 0.03 0.02 0.02 0.02
0.04 0.05 0.04 0.08 1 0.01 0.01 0.01 0.01
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1 Trial A Trial A Trial A Trial A Trial A Trial A Trial A
CHO g/min 
Cyc 1
CHO g/min 
Cyc 4
CHO g/min 
Cyc 5
CHO g/min 
Cyc 8
FAT 
g/min Cyc 
1
FAT 
g/min 
Cyc 4
FAT g/min 
Cyc 5
2.137750 2.070224 1.815559 2.314850 0.379075 0.374362 0.360249
1.857730 1.917795 1.986907 1.307758 0.477991 0.468166 0.424115
2.278128 2.030885 2.090739 1.700977 0234468 0.381779 0.347948
1.545752 1.689867 1.929732 1.435200 0.450999 0.387261 0.298513
1.960514 2.141775 2.316514 2.091087 0.449693 0.353800 0.349785
1.742473 1.733543 2.012871 1.394088 0.350411 0.353970 0.264450
1.888623 2.086391 2.284159 3-526332 0.445023 XXXXXX 0.298242
1.764141 1.839510 2.118516 2.107951 0.371587 0.308860 0.194375
1.90 1.94 2.07 1.98 0.39 0.38 0.32
0.23 0.17 0.17 0.73 0.08 0.05 0.07
0.08 0.06 0.06 0.26 0.03 0.02 0.02
Trial B Trial B Trial B Trial B Trial B Trial B Trial B
CHO g/min 
Cyc 1
CHO g/min 
Cyc 4
CHO g/min 
Cyc 5
CHO g/min 
Cyc 8
FAT 
g/min Cyc 
1
FAT 
g/min 
Cyc 4
FAT g/min 
Cyc 5
1.884400 1.482790 1.414639 0.884860 0.458843 0.577969 0.622035
2.145322 1.771760 1.725836 1.639436 0.378562 0.522747 0.557984
2.203704 1.677097 1.869160 0.867645 0.275097 0.536427 0.455374
2.030501 1.472790 1.683363 1.158822 0.210572 0.411164 0.358930
1.917633 1.687053 1.948420 1.318530 0.436336 0.517541 0.463592
1.627101 1.242297 1.588835 0 851780 0.419150 0.568750 0.446252
1.627202 1.263811 1.755123 1.681576 0.550222 0.651004 0.490731
1.872860 1.669338 1.773538 1.332744 0.384541 0.482284 0.409624
1.91 1.53 1.72 1.22 0.39 0.53 0.48
0.21 0.20 0.16 0.34 0.11 0.07 0.08
0.08 0.07 0.06 0.12 0.04 0.02 0.03
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
FAT CHO CHO CHO CHO FAT FAT FAT
g/min kcal/min kcal/min kcal/min kcal/min kcal/min kcal/min kcal/min
Cyc 8 Cyc 1 Cyc 4 Cyc 5 Cyc 8 Cyc 1 Cyc 4 Cyc 5
0.383589 8.551001 8.280895 7.262236 9.259399 3.411675 3.369260 3.242242
0.376298 7.430921 7.671182 7.947630 5.231032 4.301917 4.213495 3.817034
0.545025 9.112513 8.123539 8.362957 6.803906 2.110212 3.436008 3.131531
0.544028 6.183010 6.759470 7.718927 5.740799 4.058987 3.485352 2.686613
0.592297 7.842055 8.567098 9.266057 8.364347 4.047233 3.184196 3.148064
0.569166 6.969891 6.934172 8.051486 5.576350 3.153700 3.185729 2.380046
0.253643 7.554490 XXXXXX 9.136637 14.105329 4.005209 XXXXXX 2.684178
0.215046 7.056566 7.358040 8.474065 8.431803 3.344280 2.779738 1.749372
0.43 7.59 7.67 8.28 7.94 3.55 3.38 2.85
0.15 0.92 0.69 0.68 2.91 0.71 0.44 0.63
0.05 0.33 0.24 0.24 1.03 0.25 0.15 0.22
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
FAT CHO CHO CHO CHO FAT FAT FAT
g/min kcal/min kcal/min kcal/min kcal/min kcal/min kcal/min kcal/min
Cyc 8 Cyc 1 Cyc 4 Cyc 5 Cyc 8 Cycl Cyc 4 Cyc 5
0.908617 7.537601 5.931162 5.658554 3.539441 4.129583 5.201718 5.598314
0.640851 8.581287 7.087039 6.903344 6.557746 3.407061 4.704721 5.021854
0.709745 8.814815 6.708387 7.476639 3.470579 2.475877 4.827846 4.098365
0.595844 8.122004 5.891160 6.733453 4.635287 1.895148 3.700476 3.230368
0.766410 7.670531 6.748211 7.793681 5.274120 3.927023 4.657872 4.172328
0.759119 6.508405 4.969188 6.355340 3.407119 3.772350 5.118752 4.016272
0.747803 6.508807 5.055243 7.020492 6.726305 4.951994 5.859040 4.416581
0.642933 7.491438 6.677353 7.094151 5.330975 3.460868 4.340559 3.686619
0.72 7.65 6.13 6.88 4.87 3.50 4.80 4.28
0.10 0.85 0.80 0.66 1.34 0.96 0.64 0.74
0.03 0.30 0.28 0.23 0.47 0.34 0.22 0.26
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
FAT 
kcal/min 
Cyc 8
Total 
kcal/min 
Cyc 1
Total 
kcal/min 
Cyc 4
Total 
kcal/min 
Cyc 5
Total 
kcal/min 
Cyc 8
% CHO 
Cyc 1
% CHO 
Cyc 4
% CHO 
Cyc 5
3.452301 11.962676 11.650155 10.504477 12.711700 71.480672 71.079698 69.134670
3.386680 11.732837 11.884677 11.764664 8.617711 63.334387 64 546827 67.555096
4.905221 11.222725 11.559547 11 494487 11.709127 81.196973 70.275581 72.756240
4.896248 10.241997 10.244822 10.405540 10.637047 60.369185 65.979381 74.180941
5.330675 11.889288 11.751294 12.414121 13.695022 65 958994 72.903446 74.641269
5.122495 10.123590 10.119901 10.431531 10.698845 68.848011 68.520159 77.184121
2.282786 11.559700 XXXXXX 11 820815 16.388116 65.351959 XXXXXX 77.292786
1.935413 10.400846 10.137779 10.223437 10.367216 67.846076 72.580400 82.888614
3.91 11.14 11.05 11.13 11.85 68.05 69.41 74.45
1.34 0.77 0.83 0.84 2.40 6.30 3.21 4.86
0.47 0.27 0.29 0.30 0.85 2.23 1.14 1.72
Trial B Trial 8 Trial B Trial B Trial B Trial B Trial B Trial B
FAT 
kcal/min 
Cyc 8
Total 
kcal/min 
Cyc 1
Total 
kcal/min 
Cyc 4
Total 
kcal/min 
Cyc 5
Total 
kcal/min 
Cyc 8
% CHO 
Cyc 1
% CHO 
Cyc 4
% CHO 
Cyc 5
8.177552 11.667184 11.132880 11.256868 11 716993 64.605146 53.276081 50.267569
5.767657 11.988348 11.791760 11.925197 12.325403 71 580233 60.101624 57.888717
6.387705 11.290692 11.536233 11.575004 9.858284 78.071522 58.150582 64.592969
5.362599 10.017151 9.591636 9.963820 9.997886 81,080971 61.419761 67.579024
6.897688 11.597555 11.406083 11.966009 12 171808 66 139213 59.163264 65.131833
6.832067 10.280754 10.087940 10.371611 10.239186 63 306685 49.258699 61.276301
6.730224 11.460801 10.914282 11.437073 13.456528 56.791902 46 317682 61.383646
5.786400 10.952306 11.017912 10.780770 11.117374 68.400556 60.604526 65.803754
6.49 11.16 10.93 11.16 11.36 68.75 56.04 61.74
0.89 0.69 0.75 0.73 1.28 7.96 5.72 5.57
0.31 0.25 0.26 0.26 0.45 2.81 2.02 1.97
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
% CHO 
Cyc 8
% FAT 
Cyc 1
% FAT 
Cyc 4
% FAT 
Cyc 5
% FAT 
Cyc 8
V02 (L/min) 
TM 1
V02 (L/min) 
TM4
V02 (L/min) 
TM 5
72.841549 28.519328 28.920302 30.865330 27.158451 2.143386 2.148255 2.151067
60.700937 36.665613 35.453173 32.444904 39.29906 1.983679 2.007776 2.056658
58.107716 18.803027 29.724419 27.243760 41.892284 2.481744 2.548488 2.631060
53.969858 39.630815 34.020619 25.819059 46 030142 1.951679 1.893507 1.991684
61 075819 34 041006 27.096554 25.358731 38.924181 2.451394 2.437685 2.424886
52.121050 31.151989 31.479841 22.815879 47.87895 1.961998 1.972899 2.091913
86.070476 34.648041 XXXXXX 22.707214 13.929524 2.397945 2.270861 2.304420
81.331410 32.153924 27.419600 17.111386 18.668590 1.806068 1.788642 1811211
65.78 31.95 30.59 25.55 34.22 2.15 2.13 2.18
12.74 6.30 3.21 4.86 12.74 0.26 0.27 0 26
4.50 2.23 1.14 1.72 4.50 0.09 0.09 0.09
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
% CHO 
Cyc 8
% FAT 
Cyc 1
% FAT 
Cyc 4
% FAT 
Cyc 5
% FAT 
Cyc 8
V02 (Umin) 
TM 1
V02 (L/min) 
TM4
V02 (L/min) 
TM 5
30.207755 35.394854 46.723919 49.732431 69.79224 2.136038 2.241521 2 223027
53.205123 28.419767 39.898376 42.111283 46.79488 1.959808 2.002237 2.080645
35.204700 21.928478 41 849418 35.407031 64.79530 2.367784 2.401815 2.487655
46.362673 18.919029 38.580239 32.420976 53.63733 1.974364 1.950173 1.971661
43.330624 33.860787 40.836736 34.868167 56.66938 2.627770 2,533887 2644822
33275293 36.693315 50.741301 38.723699 66.72471 1.991565 2.003931 2.095295
49.985439 43.208098 53.682318 38.616354 50.01456 2.442497 2.478612 2.462017
47.951742 31.599444 39.395474 34.196246 52.04826 1.787257 1.862563 1.871078
42.44 31.25 43.96 38.26 57.56 2.16 2.18 2.23
8.50 7.96 5.72 5.57 8.50 0.29 0.26 0.27
3.00 2.81 2.02 1.97 3.00 0.10 0.09 0.10
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
V02 VC02 VC02 VC02 VC02
(L/min) (L/min) TM (L/min) TM (Umin) TM (Umin) TM RER TM RER TM RER TM
TM8 1 4 5 8 1 4 5
2.344155 1.960472 1.940766 1.935494 2.013461 0.914661 0.903415 0.899783
1.512281 1.768418 1.784535 1.816702 1.324222 0.891484 0.888812 0.883327
2.915075 2.326912 2.284646 2.378702 2.567817 0.937612 0.896471 0.904085
1.930735 1.714796 1.684119 1.784709 1.630810 0.878626 0.889418 0.896080
2.541218 2.194387 2.239462 2.245879 2.228937 0.895159 0.918684 0.926179
2.200944 1.749316 1.768425 1.840141 1.848309 0.891599 0.896359 0.879645
2.300543 2.108554 2.027683 2.109648 2.086819 0.879317 0.892914 0.915479
1.824138 1.614018 1.649762 1.688388 1.686047 0.893664 0.922355 0 932187
2.20 1.93 1.92 1.97 1.92 0.90 0.90 0.90
0.44 0.26 0.24 0.24 0.39 0.02 0.01 0.02
0.1 S 0.09 0.09 0.09 0.14 0.01 0.00 0.01
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
V02 VC02 VC02 VC02 VC02
(L/min) (L/min) TM (L/min) TM (Umin) TM (Umin) TM RER TM RER TM RER TM
TM8 1 4 5 8 1 4 5
2.399052 1.85253 1.824078 1.802805 1.861452 0.867274 0.813768 0.810969
1.818668 1.754209 1.683739 1.697054 1.434578 0.895092 0.840929 0.815638
XXXXXX 2.162159 2.059569 2.187138 XXXXXX 0.913157 0.857505 0.879197
1.990186 1.810673 1.668107 1.747226 1.572371 0.917092 0.855364 0.886170
2.607763 2.314896 2.215600 2.237038 2.116581 0.880936 0.874388 0.845818
1.717603 1.772444 1.656798 1.784455 1.359973 0.889975 0.826774 0.851649
2.451079 2.136615 2.079362 2.149026 2.014897 0.874767 0.838922 0.872872
1.977393 1.591525 1.594843 1.618472 1.581215 0.890485 0.856263 0.864994
2.14 1.92 1.85 1.90 1.71 0.89 0.85 0.85
0.34 0.25 0.24 0.25 0.29 0.02 0.02 0.03
0.12 0.09 0.08 0.09 0.10 0.01 0.01 0.01
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
RER TM 
8
CHO g/min 
TM 1
CHO g/min 
TM4
CHO g/min 
TM5
CHO g/min 
TMB
FAT 
g/min 
TM 1
FAT
g/min
TM4
FAT 
g/min 
TM 5
0.858928 2.039879 1.934587 1.901573 1.636510 0.305466 0.346507 0.360007
0.875645 1.678692 1.674673 1.664122 1.170788 0.359486 0.372812 0.400727
0.880875 2.621051 2.214493 2.377392 2.326177 0.258569 0.440616 0.421438
0.844658 1.537432 1.584584 1.727120 1.222526 0.395595 0.349678 0.345648
0.877114 2.115486 2.364583 2.434865 1 984354 0.429202 0.331032 0.298942
0.839780 1.661374 1.713328 1.657601 1 344776 0.355179 0.341472 0.420459
0.907098 1.896517 1.936494 2.201710 2.110283 0.483283 0.406107 0.325269
0.924298 1.546304 1.764876 1.868178 1.816031 0.320724 0.231930 0.205114
0.88 1.89 1.90 1.98 1.70 0.36 0.35 0.35
0.03 0.37 0.27 0.32 0.43 0.07 0.06 0.07
0.01 0.13 0.10 0.11 0.15 0.03 0.02 0.03
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
RER TM 
8
CHO g/min 
TM 1
CHO g/min 
TM4
CHO g/min 
TM5
CHO g/min 
TM8
FAT 
g/min 
TM 1
FAT
g/min
TM4
FAT 
g/min 
TM 5
0.775911 1.572330 1.104272 1.066846 0.768650 0.473458 0.697130 0.701771
0.788807 1.690667 1.233832 1.042725 0.689406 0.343350 0.531892 0.640597
XXXXXX 2.237237 1.661213 1.966105 XXXXXX 0.343394 0.571551 0.501863
0.790062 1.900854 1.329832 1.620846 0.765791 0.273364 0.471050 0.374806
0.811646 2 097635 1.947203 1.688644 1.259524 0.522500 0.531539 0.680999
0.791785 1.671697 1.105812 1.393373 0.674372 0.365932 0.579712 0.519103
0.822045 1.881183 1.504753 1.874994 1.299818 0.510823 0.666748 0.522695
0.799646 1.504344 1.277708 1.357887 0.847097 0.326872 0.447092 0.421852
0.80 1.82 1.40 1.50 0.90 0.39 0.56 0.55
0.02 0.26 0.29 0.35 0.27 0.09 0.09 0.12
0.01 0.09 0.10 0.12 0.09 0.03 0.03 0.04
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A T rial A
FAT
g/min
TM8
CHO 
kcal/min 
TM 1
CHO
kcal/min
TM4
CHO
kcal/min
TM5
CHO
kcal/min
TMB
FAT 
kcal/min 
TM 1
FAT
kcal/min
TM4
FAT
kcal/min
TM5
0.552259 8.159514 7.738347 7.606291 6.546040 2.749197 3.118560 3.240062
0.314059 6.714769 6.698693 6.656488 4.683152 3.235373 3.355312 3.606539
0.579921 10.484205 8.857971 9.509566 9.304706 2 327125 3.965545 3.792941
0.500875 6.149729 6.338336 6.908481 4 890105 3.560351 3.147102 3.110834
0.521509 8.461944 9.458333 9.739462 7.937414 3.862815 2.979292 2.690475
0.588900 6.645497 6.853312 6.630403 5 379103 3.196610 3.073244 3.784133
0.356919 7.586069 7.745975 8.806841 8.441134 4.349547 3.654965 2.927423
0.230612 6.185214 7.059505 7 472712 7264123 2.886512 2.087366 1.846030
0.46 7.55 7.59 7.92 6.81 3.27 3.17 3.12
0.14 1.47 1.09 1.27 1.72 0.65 0.55 0.65
0.05 0.52 0.39 0.45 0.61 0.23 0.19 0.23
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
FAT
g/min
TMB
CHO 
kcal/min 
TM 1
CHO
kcal/min
TM4
CHO
kcal/min
TM5
CHO
kcal/min
TMB
FAT 
kcal/min 
TM 1
FAT
kcal/min
TM4
FAT
kcal/min
TM5
0.897792 6.289318 4 417090 4.267384 3.074599 4.261125 6.274168 6.315937
0.641430 6.762669 4.935327 4.170901 2.757622 3 090153 4.787025 5.765373
XXXXXX 8.948947 6.644851 7.864421 XXXXXX 3.090544 5.143957 4.516771
0.697751 7.603415 5.319326 6.483386 3.063164 2 460276 4.239452 3.373258
0.820274 8.390540 7.788811 6.754577 5 038097 4 702496 4.783854 6.128994
0.597242 6 686786 4.423250 5.573493 2.697486 3.293389 5.217409 4.671925
0.728424 7.524732 6.019010 7.499975 5.199271 4.597406 6.000728 4.704255
0.661617 6.017375 5.110834 5.431549 3.388387 2.941852 4.023832 3.796668
0.72 7.28 5.58 6.01 3.60 3.55 5.06 4.91
0.11 1.03 1.17 1.38 1.06 0.84 0.78 1.07
0.04 0.36 0.41 0.49 0.38 0.30 0.28 0.38
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
FAT
kcal/min
TM8
Total 
kcal/min 
TM 1
Total 
kcal/min 
TM 4
Total 
kcal/min 
TM 5
Total
kcal/min
TMB
% CHO 
TM 1
% CHO 
TM4
% CHO 
TM 5
4.970331 10.908712 10.856907 10.846353 11.516371 74.798147 71.275799 70.127634
2.826527 9.950142 10.054005 10.263026 7.509679 67.484154 66.627109 64.858916
5.219288 12.811330 12 823517 13.302507 14.523994 81.835415 69.075992 71.487023
4.507873 9.710080 9.485438 10 019315 9.397977 63.333450 66.821756 68.951629
4.693583 12.324760 12.437625 12.429937 12.630998 68.658089 76.046136 78.35488
5.300104 9.842107 9.926556 10.414536 10.679207 67.521077 69.040177 63.664891
3.212272 11.935616 11.400941 11.734264 11.653405 63 558254 67.941546 75.05235
2.075508 9.071726 9.146872 9.318742 9.339631 68.181231 77 179450 80.190141
4.10 10.82 10.77 11.04 10.91 69.42 70.50 71.59
1.22 1.39 1.36 1.34 2.18 6.14 4.06 5.96
0.43 0.49 0.48 0.47 0.77 2.17 1.43 2.11
Trial B Trials Trial B Trial B Trial B Trial B Trial B Trial B
FAT
kcal/min
TMB
Total 
kcal/min 
TM 1
Total
kcal/min
TM4
Total 
kcal/min 
TM 5
Total
kcal/min
TMB
% CHO 
TM 1
% CHO 
TM4
% CHO 
TM 5
8.080128 10.550443 10.691258 10.583321 11.154727 59.611884 41.314968 40.32179
5.772873 9.852822 9.722352 9.936274 8.530495 68.636874 50.762685 41.97651
XXXXXX 12.039491 11.788809 12.381192 XXXXXX 74.329947 56.365757 63.51910
6.279759 10.063691 9.558778 9.856644 9.342923 75.552947 55.648599 65.77681
7.382465 13.093037 12.572665 12 883571 12.420563 64.083991 61.950360 52.42783
5.375179 9.980175 9.640659 10.245418 8.072665 67.000692 45.881197 54.39986
6.555815 12 122138 12.019738 12.204230 11.755087 62.074294 50.076053 61.45390
5.954555 8.959227 9.134665 9.228217 9 342942 67.163998 55.949874 58.85805
6.49 10.83 10.64 10.91 10.09 67.31 52.24 54.84
0.95 1.42 1.32 1.37 1.68 5.56 6.58 9.54
0.34 0.50 0.47 0.48 0.59 1.96 2.33 1 3.37
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
%CHO % FAT TM % FAT TM % FAT TM %FAT TM Avg RPM's Avg RPM's Avg RPM's
TM8 1 4 5 8 Cycl Cyc2 Cyc 3
56.841171 25.20185 28.72420 29.87237 43.15883 XXXXX XXXXX XXXXX
62.361551 32.51585 33.37289 35.14108 37.63845 86 86 86
64.06438 18.16458 30.92401 28 51298 35.93562 73 73 82
52.03359 36.66655 33.17824 31.04837 47.96641 66 68 65
62.84075 31.34191 23.95386 21.64512 37.15925 78 81 81
50.36987 32.47892 30.95982 36.33511 49.63013 83 86 89
72.434910 36.44175 32.05845 24.94765 27.56509 88 88 87
77 777412 31.81877 22.82055 19.80986 22.22259 91 92 89
62.34 30.58 29.50 28.41 37.66 80.71 82.00 82.71
9.44 6.14 4.06 5.96 9.44 8.90 8.62 8.42
3.34 2.17 1.43 2.11 3.34 3.15 3.05 2.98
Trial B Trial B Trial B Trial B Trial B Trial B Trial B Trial B
% CHO % FAT TM % FAT TM % FAT TM % FAT TM Avg RPM's Avg RPM's Avg RPM's
TM8 1 4 5 8 Cyc 1 Cyc2 Cyc 3
27.56319 40.38812 58.68503 59.67821 72.43681 XXXXX XXXXX XXXXX
32.32664 31.36313 49.23732 58.02349 67.67336 96 99 100
XXXXXX 25.67005 43.63424 36.48090 XXXXXX 74 73 76
32.78593 24.44705 44.35140 34.22319 67.21407 68 70 71
40.56255 35.91601 38.04964 47.57217 59.43745 68 69 76
33.41506 32.99931 54.11880 45.60014 66.58494 88 91 92
44.22997 37.92571 49.92395 38.54610 55.77003 87 84 86
36.26681 32.83600 44.05013 41.14195 63.73319 98 99 103
35.31 32.69 47.76 45.16 64.69 82.71 83.57 86.29
5.58 5.56 6.58 9.54 5.58 12.68 13.16 12.55
1.97 1.96 2.33 3.37 1.97 4.48 4.65 4.44
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Avg RPM's 
Cyc 4
Avg RPM's 
Cyc 5
Avg RPM's 
Cyc 6
Avg RPM's 
Cyc 7
pre
Avg RPM's weight 
Cyc 8 (kg)
post
weight
(kg)
weight
difference
(kg)
XXXXX XXXXX XXXXX XXXXX XXXXX 84.6 82.7 -1.9
86 86 74 43 35 63.8 61.8 -2.0
XXXXX 80 XXXXX 72 69 81.5 78.6 -2.9
63 70 64 57 58 67.0 66.4 -0.6
83 84 87 90 93 89.2 86.4 -2.8
88 88 91 89 88 65.2 64.6 -0.6
87 89 86 87 102 84.3 82.4 -1.9
86 84 85 93 86 61.7 61.1 -0.6
82.17 83.00 81.17 75.86 75.86 74.66 73.00 -1.66
9.54 6.45 10.15 19.33 23.32 11.24 10.52 0.96
3.37 2.28 3.59 6.83 8.24 3.97 3.72 0.34
Trial B Trial B 1 Trial B Trial B Trial B Trial B Trial B Trial B
Avg RPM's 
Cyc 4
Avg RPM's 
Cyc 5
Avg RPM's 
Cyc 6
Avg RPM's 
Cyc 7
pre
Avg RPM's weight 
Cyc 8 (kg)
post
weight
(kg)
weight
difference
(kg)
XXXXX XXXXX XXXXX XXXXX XXXXX 84.4 82.7 -1.7
100 XXXXX 87 46 31 62.9 61.9 -1.0
71 69 71 70 42 81.3 78.6 -2.7
70 65 64 57 47 67.9 66.2 -1.7
77 79 80 82 76 89.6 86,1 -3.5
92 91 91 92 90 65.6 643 -1.3
84 82 86 91 96 84.8 82.2 -2.6
100 95 95 98 101 62.5 60.2 -2.3
84.86 80.17 82.00 76.57 69.00 74.88 72.78 -2.10
12.81 11.81 11.11 19.56 28.58 11.20 10.63 0.83
4.53 4.17 3.93 6.92 10.10 3.96 3.76 0.29
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Total Void 
(L)
Urinary
Nitrogen
(mg/dL)
Time pre 
biopsy to 
Bkfast 
(min)
Time Bkfst 
to Exer 
(min)
Time Exer 
to post 
biopsy (min)
Blood
Glucose
Pre
(mmol/L)
Blood
Glucose
Lunch
(mmol/L)
Blood
Glucose
Post
(mmol/L)
0.675 732 22.53 33.93 11.25 2.98 4.52 4.64
0.250 810 15.05 35.63 10.62 3.71 5.24 5.45
1.925 709 25.12 29.82 11.63 3.05 4.27 5.52
0.925 976 31.32 25.22 14.45 3.72 4.62 5.13
1.700 463 26.37 34.53 13.17 2.95 3.43 4.37
0.900 362 28.52 32.37 12.72 3.85 5.06 5.54
1.100 731 22.23 29.45 11.45 4.28 4.73 5.93
1.300 411 25.88 35.12 12.62 3.38 41 6 4.68
1.10 649.25 24.63 32.01 12.24 3.49 4.50 5.16
0.54 215.03 4.88 3.59 1.24 0.48 0.57 0.54
0.19 76.03 1.73 1.27 0.44 0.17 0.20 0.19
Trial B Trials Trials Trials Trials Trials Trial B Trials
Total Void 
(L)
Urinary
Nitrogen
(mg/dL)
Time pre 
biopsy to 
Bkfast 
(min)
Time Bkfst 
to Exer 
(min)
Time Exer 
to post 
biopsy (min)
Blood
Glucose
Pre
(mmol/L)
Blood
Glucose
Lunch
(mmol/L)
Blood
Glucose
Post
(mmol/L)
0.525 993 26.72 35.12 12.62 2.94 3.39 2.13
0.300 1049 21.85 36.05 9.28 3.59 4.01 3.14
2.050 372 23.27 30.37 XXXXX 2.95 2.77 2.62
1.250 408 24.15 27.43 16.17 3.22 2.95 2.35
1.275 353 28.53 36.78 12.18 3.81 3.31 2.72
1.325 449 22.88 31.08 9.85 4.26 4.33 2.01
0.725 804 21.78 33.82 12.62 4.10 4.10 4.15
1.775 342 21.58 33.03 10.57 3.27 3.38 3.93
1.15 596.25 23.85 32.96 11.90 3.52 3.53 2.88
0.60 301.61 2.53 3.17 2.32 0.51 0.56 0.80
0.21 106.63 0.90 1.12 0.82 0.18 0.20 0 28
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Trial A Trial A Trial A Trial A Trial A Trial A Trial A Trial A
Insulin
Pre
(UlU/mL)
Insulin
Lunch
(plU/mL)
Insulin
Post
(MlU/mL)
Lactate
Pre
Lactate
Lunch
Lactate
Post
Musde
Glycogen
pre
(mmoUg wet)
Musde 
Glycogen post 
(mmol/g wet)
5.587 16.093 13.351 1.55 1.53 1.88 125.0099 51.44777
5.696 7.964 7.590 1.68 1.95 2.34 124.4962 49.40293
4.837 13.197 14.440 1.74 1.67 2.44 164.2432 77.06331
3.434 10.840 8.180 2.05 3.09 2.24 108.2394 67.21273
5.779 16.183 13.637 1.23 1.37 1.79 115.2567 21.50329
7.028 14.128 13.199 1.22 1.73 1.81 103.6237 22.28795
3.393 8.208 11.081 1.41 1.74 1.54 228.7633 163.0158
4.622 21.565 15.882 2.16 1.82 1.90 230.41 143.66
5.05 13.52 12.17 1.63 1.86 1.99 150.00 74.45
1.32 3.45 2.77 0.35 0.53 0.31 52.44 52.61
0.47 1.22 0.98 0.12 0.19 0.11 18.54 18.60
Trial B Trials Trial B Trial B Trial B Trial B Trial B Trial B
Insulin
Pre
(MlU/mL)
Insulin
Lunch
(plU/mL)
Insulin
Post
(MlU/mL)
Lactate
Pre
(mmol/L)
Lactate
Lunch
(mmol/L)
Lactate
Post
(mmol/L)
Musde
Glycogen
pre
(mmol/g wet)
M usde 
Glycogen post 
(mnrioVg wet)
3.633 3.095 2.880 1.52 1.50 2.07 134.2353 30.09238
6.314 4.354 3.753 1.38 2.55 4.26 101.2918 31.75072
3.933 3.562 2.701 1.52 1.73 2.59 222.2708 73.41455
3.970 4.150 2.641 2.28 3.82 3.41 129.1247 34.26359
8.511 5.867 2.703 2.60 1.86 2.30 187.2168 17.51272
9.023 4.309 2.045 1.61 1.52 2.29 101.9649 16.52
3.684 4.476 2.442 1.38 1.62 1.57 217.38 143.85
5.950 5.754 2.992 1.87 1.84 2.31 189.95 57.27
5.63 4.45 2.77 1.77 2.06 2.60 160.43 50.58
2.20 0.96 0.49 0.45 0.79 0.85 49.62 42.36
0.78 0.34 0.17 0.16 0.28 0.30 17.54 14.98
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Raw
Trial A Trial A Trial A Trial A Trial A
Musde 
Glycogen 
pre 
(mmol/g wet)
Muscle 
Glycogen post 
(mmol/g wet)
C hange 
(pre to post) 
(mmol/g wet)
% C hange 
(pre to post)
Rate of Muscle 
Glycogenolysis
112.5089 46.3030 73.56 -143% 9.20
112.0465 44.4626 75.09 -152% 9.39
147.8189 69.3570 87.18 -113% 10.90
97.4154 60.4915 41.03 -61% 5.13
103.7310 19.3530 93.75 -436% 11.72
93.2613 20.0592 81.34 -365% 10.17
205.8869 146.7142 65.75 -40% 8.22
207.3650 129.2982 86.74 -60% 10.84
135.00 67.00 75-55 -1.71 9.44
47.19 47.35 16.55 1.48 2.07
16.69 16.74 5.85 0.52 0.73
Trial B Trial B Trial B Trial B Trial B
M usde 
Glycogen 
pre 
(mmol/g wet)
Musde 
Glycogen post 
(mmol/g wet)
C hange 
(pre to post) 
(mmol/g wet)
C hange (pre 
to post) 
(mmol/g wet)
Rate of Muscle 
Glycogenolysis
120.8118 27.0831 104.14 -346% 13.02
91.1627 28.5756 69.54 -219% 8.69
200.0437 66.0731 148.86 -203% 18.61
116.2123 30.8372 94.86 -277% 11.86
168.4951 15.7614 169.70 -969% 21.21
91.7684 14.8682 85.44 -517% 10.68
195.6414 129.4691 73.52 -51% 9.19
170.9531 51.5397 132.68 -232% 16.59
144.39 45-53 109.84 -3.52 13.73
44.66 38.12 36.69 2.83 4.59
15.79 13.48 12.97 1.00 1.62
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